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Abstract 
This study investigates the problem of ineffective antibacterial treatment against 
multi-drug resistant pathogens. The number of antibiotic-resistant pathogens has increased 
over time as a result of bacterial evolution due to antibiotic selective pressure. The goal of this 
study was to characterize a novel antimicrobial drug combination which causes minimal 
selective pressure and suppresses the emergence of resistance. We suggested the combination 
of antibiotics with human transferrin and studied its effects on antibiotic susceptibility and 
resistance emergence in vitro. First, the in vitro pharmacodynamics of the monotherapy or 
combination therapy groups were studied over 24 hours. It was found that in most cases there 
is no evidence of antagonism or synergy between transferrin and antibiotics. Transferrin was 
characterized to possess a mostly bacteriostatic mode of action. Then, we discovered that 
transferrin decreases and sometimes prevents the emergence of resistance. For both a high 
inoculum 24 hours and and lower inoculum 20-days passage experiments, more antibiotic 
resistant mutants were selected when bacteria were cultured in antibiotic alone vs antibiotic + 
transferrin. Highly resistant strains with increased virulence resulted from 20 days passage. 
Virulence was tested by a phagocytosis assay using a murine macrophage cell line 
(RAW264.7), and the macrophage uptake was significantly lower for monotherapy passaged 
strains. Thus, adjunctive transferrin can improve the antibacterial therapy and decrease the 
emergence of resistance in Gram-negative pathogens.   
Абстракт 
 В работе рассматривается проблема повышения эффективности 
антибиотикотерапии инфекций, вызванных полирезистентными грамотрицательными 
патогенами. Доля таких патогенов постоянно увеличивается, как результат 
направленной эволюции бактерий в ответ на селективное давление используемых в 
клинике антибиотиков. Задачей работы было разработать методику антибактериальной 
терапии, оказывающую минимальное селективное давление и замедляющую 
формирование резистентности. В работе предложена комбинация антибиотиков с 
человеческим трансферрином и изучены ее эффекты in vivo и in vitro. На первом этапе 
изучалась суточная динамика антибактериального действия комбинации по сравнению 
Abstract P7
с монотерапией антибиотиками и трансферрином in vitro. Выяснено, что в большинстве 
случаев нет доказательств синергизма или антагонизма между компонентами 
комбинации. Кроме того, установлен преимущественно бактериостатический тип 
действия трансферрина. Далее было показано, что добавление трансферрина замедляет 
и в некоторых случаях предотвращает формирование резистентности к антибиотикам у 
изначально чувствительных штаммов. Такое явление обнаружено как в 24-х часовом 
эксперименте с высокой дозой бактерий, так и в 20-ти дневном эксперименте с низкой 
дозой бактерий. В результате 20-ти дневного эксперимента получен штамм, который 
вместе с резистентностью приобрел повышенную вирулентность, что было доказано 
снижением фагоцитарной активности макрофагов, клеточная линия RAW264.7. Таким 
образом, применение антибиотиков в комбинации с трансферрином может повышать 
эффективность антибактериальной терапии и предупреждать формирование 
резистентных штаммов бактерий. 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Introduction 
Purpose and definitions of the thesis project 
 Our goal was to determine if transferrin had in vitro and in vivo synergy with standard 
antimicrobial agents used to treat these pathogens, and to determine if combination therapy 
with transferrin plus antibiotic could reduce the emergence of resistance to the antibiotic in 
these Gram-negative bacterial pathogens. The purpose of research project is to study the in 
vitro and in vivo effect of adjunctive human transferrin on susceptibility and emergence of 
resistance in Gram-negative pathogens. There are 2 main aims to answer the following 
questions: 
1. Hypothesis: Does the addition transferrin improve the rate of killing of widely-
used antibiotics in Gram-negative bacteria? Two possible outcomes are expected. 
Either a decrease of drug efficacy or improvement of the rate of killing. A decrease in 
efficacy is plausible because transferrin may induce the bacteria to enter a 
metabolically inactive state due to the starvation of iron. It has previously been 
observed for other bacteria that a decrease in cellular metabolism may provide a 
mechanism for antibiotic tolerance. Alternatively, as transferrin and the antibiotic to be 
tested in combination have different mechanisms of action it may also be possible that 
these drugs will act synergistically together. 
2. Hypothesis: Does the addition of transferrin decrease the emergence of 
resistance? Combination therapy, as compared to monotherapy, has previously been 
used to suppress the emergence of resistance. Most notably the drug combinations 
have been standard practice in the treatment of bacteria that are prone to developing 
drug resistance such as Mycobacterium tuberculosis and also in viral infections such 
as HIV. 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Chapter 1. Literature Review 
1. Antibiotic resistance crisis 
 The discovery of antibiotics, subsequently named «miracle drugs», in the 1930s 
revolutionized medicine. Regrettably, the public health gains supported by antibiotics are now 
seriously threatened by the increasing emergence of antibiotic resistance [1]. Historically, 
clinical emergence of antibiotic resistance has rapidly followed use of antibiotics. Indeed 
Alexander Fleming, who discovered penicillin, acknowledged the problem of antibiotic 
resistance emerging under the selective pressure of antibiotics, and in his Nobel Lecture 
strongly suggested physicians and the public should not misuse antibiotics: «...Then there is 
the danger that the ignorant man may easily underdose himself and by exposing his microbes 
to non-lethal quantities of the drug make them resistant.» [2].  
 Over the last 80 years, medical use of antibiotics has been a driving factor of the 
emergence of microbial pathogens resistant to clinically used antibiotics, resulting in the 
current antibiotic resistance crisis [3]. One paradox of combating antibiotic resistance is that 
the use of a new antibiotic will ultimately select for antibiotic-resistant mutants and thus 
render the antibiotic less effective. 
 However, it is critical to emphasize that medical use of antibiotics is not a unique 
source of antibiotic pressure against bacteria. Bacteria have been living in the environment 
full of antibiotics throughout their entire history. Antibiotics are naturally produced by 
microbes as a mechanisms to suppress or kill other microbes in the community [4]. The 
ongoing discussion about environmental reservoirs of antibiotic resistance considers their 
potential impact on clinical pathogens [4].  Bacteria have evolved a broad spectrum of 
antibiotic resistance mechanisms. The genetic resistance determinants can be spread both 
within a single species and across diverse species through a variety of horizontal gene transfer 
mechanisms. These features allow for the rapid emergence and broad spread of resistance 
genes within bacteria. The largest database has currently collected 3661 unique antibiotic 
resistance genes which were described in 2276 scientific publications [5]. 
 The result of bacterial evolution is reflected in the global statistics showing the rise of 
antibiotic resistance among clinically significant pathogens over time [22-23].  For example, 
carbapenems, a relatively new class of antibiotics, are already obsolete for Acinetobacter 
baumannii infections [24]. 50% of A. baumannii isolates were imipenem-resistant, depending 
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on intensive care unit (ICU) status, in the U.S.A. in 2009-2012 (Fig. 1.1) [24]. In 2014, the 
Centers for Disease Control and Prevention (CDC) reported that in the U.S. the percent of 
Acinetobacter resistant to at least 3 different antibiotics (multidrug-resistant Acinetobacter) 
ranged from 5.0% to 88.1% (54.8% nationally) [26]. In Russia the majority of isolated clinical 
strains of A. baumannii are drug-resistant: 93% of them are resistant to cefoperazone, 61.2% 
to amicacin, 51.9% to levofloxacin [25]. 
The problem of antibiotic resistance is especially relevant to the Intensive Care Unit 
(ICU) in the hospitals. Patients in the ICU are at high risk for acquiring hospital acquired 
infections (HAI) due to the broad use of invasive devices which disrupt the integrity of body 
surface. In 2000, The National Nosocomial Infection Surveillance (NNIS) system reported 
that 83% of episodes of nosocomial pneumonia were associated with mechanical ventilation; 
97% of  urinary  tract  infections  occurred in  patients  with  a  urinary  catheter;  and 87% of 
primary bloodstream infections were in patients with a central line [28]. Hospital-acquired 
infections in ICUs are a significant mortality risk factor. In some patient groups, e.g. elderly 
patients  treated  with  central  catheter  and/or  mechanical  ventilation  devices  in  ICUs,  in-
hospital mortality was 4 times higher than in those without nosocomial infections [29]. As a 
direct consequence, ICUs generally utilize the most antibiotics in the hospital. For instance, in 
Switzerland  the  median  of  total  antibiotic  use  in  hospitals  was  53.4  defined  daily  doses 
(DDD) per 100 bed-days, whereas the median in ICUs was 114.3 defined daily doses (DDD) 
per 100 bed-days [30].
The crisis of antibiotic resistance among clinically important pathogens together with 
the  overuse  and  misuse  of  existing  antibiotics  support  the  idea  that  new  strategies  of 
antimicrobial therapy with novel mechanisms of action are needed.
Figure 1.1. Resistance of Acinetobacter baumannii to carbapenems: A in the U.S., from [23]; B worldwide, 
from[22].
A B
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In 2013 CDC issued a list of four core actions to deal with antibiotic resistance in 
medicine:  1) preventing infections and the spread of resistance, 2) tracking resistance genes 
and surveillance,  3) improving antibiotic prescribing/stewardships,  and 4) developing new 
drugs and diagnostic test. In reference to the last point, the CDC acknowledges the nature of 
resistance: «Because antibiotic resistance occurs as part of a natural process in which bacterial 
evolve,  it  can  be  slowed  down  but  not  stopped.  Therefore,  we  will  always  need  new 
antibiotics  to  keep up with resistant  bacteria  as  well  as  new diagnostic  tests  to  track the 
development  of  resistance»  [6].  However,  despite  the  urgent  need  big  pharmaceutical 
companies have been withdrawing from the antibiotic market due to economical reasons over 
the past 20 years.
To confront the outlook of the lack of new antibiotics in the near future, several new 
approaches have been suggested to improve patient care. One idea is to use a combination of 
synergistic antibiotics. The strategy was found to be beneficial in some conditions, however 
some  recent  studies  suggest  that  specific  antibiotic  combinations  function  to  promote 
antibiotic  resistance  [7].  Another  approach  is  to  use  a  non-vaccine  immunotherapy,  i.e. 
passive  immunization  by  antibodies.  Effective  antibody  therapies  have  been  developed 
against particular bacterial infections such as botulism [8], but not for all pathogens. Broadly 
protective  antibodies  also  remain  elusive.  One  approach  had  been  to  target  bacterial 
lipopolysaccharide (LPS), a common feature of bacteria. The use of a monoclonal antibody to 
target  deacetylated  PNAG  (poly-β-1,6  -N-acetylglucosamine),  a  component  of 
lipopolysaccharide, showed a survival benefit in animal models of infections (presumably by 
blocking  biofilm  formation)  [9-10],  but  this  success  has  yet  to  be  translated  to  humans 
(clinical trial had been prematurely discontinued and hadn’t been resumed since 2012) [11]. 
Other  strategies  that  have  been  suggested  are  to  manipulate  host  targets,  such  as 
enhancement of  host  defense mechanisms,  rather than focusing on microbial  targets.  It  is 
believed that interventions that do not directly act on the bacterium will be exert less selective 
pressure and the emergence of resistant mutants will be less likely. The main efforts in this 
area were aimed to modulate human immune response by immune adjuvants. Priming the 
long term memory response by vaccination is the best characterized example of modulating 
the  immune  response.  Not  enough  evidence  of  immunity  modulation  (such  as  Toll-like 
receptor agonists, IL-7, IL-12) being safe and effective in humans were found so far, on the 
contrary immunomodulators can cause harm by exacerbating inflammation [12].
Thus, our goal was to develop completely new paradigm of antimicrobial therapy with 
following requirements: 1) improvement of host defenses, 2) no interaction with microbial 
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targets,  3)  no relation to  host  immune system. One novel  solution proposed by Dr.  Brad 
Spellberg was to starve bacteria of iron, an essential element required for growth, by the use 
of the iron-binding protein transferrin and combine it with traditional antibiotics to improve 
antibacterial therapy in patients [19].
2. Transferrin as antimicrobial agent 
 Iron starvation results in broad growth arrest in diverse microbial species and it has 
been hypothesized that adjunctive transferrin therapy in combination with traditional 
antibiotics, would be superior as compared to antibiotics alone [19-21]. Humans, and other 
mammals, have evolved to exploit this susceptibility feature of bacteria and have developed 
mechanisms to maintain extremely low level of free iron in the body fluids to prevent 
infections. Iron starvation is an example of nutritional immunity which is the process of 
restricting nutrients from pathogens [31]. Iron starvation is a promising antibacterial strategy 
[19] and this is contrasted with iron overload which can  promote infections [21]. 
Additionally, animal studies have shown that the additional supplementation of iron to the 
host will exacerbate disease [33]. 
 The level of iron can be decreased by different sequestrating agents. Among these, 
transferrin is a natural human iron-binding protein and is a potential candidate to be used in 
humans (discussed below). In vitro transferrin antibacterial activity has been demonstrated 
many years ago [27, 31] and since then multiple evidence of that have been found [38].  
 The growth of various pathogens can be reduced by transferrin in vitro. The list 
includes but is not limited both Gram-negative and Gram-positive bacteria: Pseudomonas 
aeruginosa, Klebsiella pneumonia, Yersinia pseudotuberculosis, and Bacillus anthracis, as 
well as fungal pathogens, such as Candida spp. and Histoplasma capsulatum [19]. Recent 
studies by the Spellberg lab demonstrated that rh-transferrin inhibits the growth of such 
bacteria as Acinetobacter baumannii, methicillin resistant Staphylococcus aureus (MRSA) 
and Candida albicans in vitro [20]. In particular, it was found that exposure to 1 ng/mL of rh-
transferrin for 1 hour significantly reduced CFUs number of those 3 species [20]. At the 60 
µg/mL concentration, transferrin mediated a  >1000-fold reduction in S. aureus CFUs at 24 
hours compared to growth control [20]. Transferrin acts synergistically with rifampin in vitro 
against S. aureus, decreasing the rifampin minimum inhibitory concentration (MIC) from 0.15 
µg/ml to 0.019 µg/ml (8-fold decrease) [20].  
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 Therapeutic activity of transferrin has been reported in mice studies as well. The 
Spellberg lab has shown rh-transferrin is beneficial in bloodstream infections caused by 
methicillin resistant Staphylococcus aureus (MRSA), Acinetobacter baumannii and Candida 
albicans [20]. Intravenous rh-transferrin in dose 90 mg/kg/day for four days remarkably 
improved murine survival in all 3 infections [20]. The addition of ferric chloride reversed the 
efficacy of the transferrin against C. albicans in mice [20]. Also in mice infected with S. 
aureus rh-transferrin reduced the number of rifampin mutants in combination therapy group 
in about 2 times compare to mice group treated with rifampine alone [20]. 
3. Clinical use of iron-sequestering anti-infective therapy 
 Despite the promising results of in vitro and in vivo studies no therapeutic options 
based on rh-transferrin have been developed for human use for an antimicrobial purpose. 
Several clinical studies had been conducted to use human transferrin to treat iron overload or 
other conditions. Data from these trials support acceptable safety profile, and commercial 
product to use in humans is available [39]. Three relevant clinical studies are reviewed below. 
Additionally, transferrin can be used as a drug delivery and targeting system in humans [38], 
but we will not discuss that application here. 
 The first study was done in 1998 in infants with hypotransferrinemia and 
hyperferritinemia. Apotransferrin was used as replacement therapy to treat iron overload. The 
study included just 2 patients, but found that exogenous apotransferrin is safe and effective 
[32]. Due to small sample this study should be considered as unreliable. 
 The second clinical trial published in 2003 recruited 26 severely ill patients with 
haematological malignancies receiving allogeneic stem cell transplantation after 
myeloablative conditioning with cyclophosphamide and total body irradiation [33]. Subjects 
were treated with either 1x or 14x doses of apotransferrin 100 mg/kg/day or higher [33]. 
Study found two positive effects of apotransferrin: 1) the number of days with intravenous 
antibacterial treatment was significantly lower in groups receiving apotransferrin than in the 
control group, and 2) there was a significant reduction in the number of days with fever and 
days with elevated CRP (markers of infection) in the patient groups who received low and 
high doses of apotransferrin respectively [33]. Overall, apotransferrin was well tolerated by 
patients. However, the trial was not randomized, the size of patient’s groups was small and 
adverse events were not measured properly, thus the study was promising but not conclusive. 
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 The third trial was done few years later by the same group of authors as second. They 
studied patients with the same disease and enrolled 20 of them in this trial [34]. Patients 
received 26-115 mg/kg of apotransferrin 6-9 times during 2 weeks. Study did not evaluate the 
effect of transferrin on infectious complications, but did appropriate analysis of adverse 
events [34]. During the study and 21 days of follow-up no toxicities or serious adverse events 
were reported and only one event possibly related to treatment (S-ALT elevation) was 
encountered [34]. The study provides the evidence that even high dose (up to 1040 mg/kg 
total) of apotransferrin is safe and well-tolerated in humans. 
 Another clinical trial of apotransferrin is ongoing and investigates it as replacement 
therapy for patients with congenital atransferrinemia [36]. Together with approval of this trial 
apotransferrin has received a European orphan drug designation for congenital 
atransferrinemia [37]. This study will provide additional information about transferrin safety 
in humans, to date no signs of toxicities were found. 
 There is some reported success of lactoferrin treatment (member of transferrin protein 
family containing very similar iron-binding domains [14]). The combination of lactoferrin 
with antibiotics to treat bacterial infections in human was first proposed and patented in 1989 
by Immuno Japan Inc. / Chugai Pharmaceutical Co Ltd [13]. Authors found that lactoferrin in 
combination with beta-lactam antibiotic remarkably potentiates the antibiotic efficacy, thus 
reducing the antibiotic requirement from 7.93 mg/mouse in antibiotic alone group to 1.25 mg/
mouse in combo group  [13]. The study utilized a murine model of intraperitoneal K. 
pneumoniae and E.coli infection, all drugs were administered orally [13]. For other patented 
technologies of the use of lactoferrin/transferrin in the treatment of bacterial infections see 
Supplementary materials, S10. 
 In 2016 Infectious Diseases Society of America included oral bovine lactoferrin in the 
guideline for the prophylaxis of Candida infections in neonates <1500 g [15]. 
Recommendation was established based on randomized clinical trial shown that «bovine 
lactoferrin is able to prevent not only late-onset sepsis but also systemic fungal 
infections» [16]. Search in the database clinicaltrials.gov by query ‘«lactoferrin» AND 
«infection»’ retrieves 38 clinical trials including the recently completed study «Prevention of 
Nosocomial Infections in Critically Ill Patients With Lactoferrin: The PREVAIL Study 
(PREVAIL)». The final study results are still pending publication [17]. 
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 Lactoferrin has some important differences from transferrin in spite of high structural 
and functional similarity. Lactoferrin is shown to have other mechanisms of antibacterial 
actions besides iron sequestrating, such as direct binding to LPS, acting as a serine protease, 
through its metabolite lactoferricin and others [18]. However, lactoferrin is a natural 
component of milk not blood, therefore in all clinical trials it was administered orally and 
produced mostly local effect in the gut.  
 Clinical trials of iron-sequestering small molecules have been reported but 
unfortunately were unsuccessful mostly due to safety reasons. Small iron-chelating molecules 
such as deferasirox (selective chelator of trivalent iron) were studied. The most recent 
example is a randomized, double-blinded, placebo-controlled phase 2 clinical trial of 
deferasirox therapy for mucormycosis (DEFEAT Mucor) was published in 2011 [35]. The 
study included 20 patients with proven or probable mucormycosis who were treated with 
either deferasirox 20 mg/kg/day or placebo for 14 days. At the result  patients treated with 
deferasirox had a higher mortality rate at 90 days compare to placebo (82% vs. 22%) and less 
global success rate (18% vs. 56%) [35]. The PI of that trial, Brad Spellberg, described the 
explanation for treatment failure as follows: «The extremely high iron affinities of microbial-
derived siderophores, which are far higher than affinities for small molecule chelators, has led 
to the perception that iron acquisition by high affinity siderophores cannot be overcome in 
vivo by chelation-based therapy. An additional problem is that small molecule chelators alter 
metabolic disposition of iron in ways that may be injurious to the host.» [19].  
 Thus, based on available clinical data, recombinant human transferrin remains a 
promising iron-depleting agents to improve antibacterial therapy in humans due to following 
reasons: 
1. Extrapolating results from apotransferrin studies, rh-transferrin is expected to be safe in 
humans even being administered in high doses to patients with severe conditions. It is 
believed that exogenous transferrin does not damage physiological iron metabolism in 
human [19]. 
2. Transferrin is a serum protein, which is able to work at systemic level compared to 
lactoferrin, which works mostly locally. The potential for systemic administration is 
important for combination therapy with antibiotics, especially in critically ill patients.  
3. Transferrin takes advantage of natural iron routing mechanisms in the body, as opposed to 
small molecule iron chelators, which take iron out of the reticuloendothelial system where 
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it is normally stored, and deliver it to the kidneys where it is normally not delivered. 
Thus transferrin may avoid some of the toxicities (bone marrow and renal) that result 
from small molecule iron sequestration. 
4. Recombinant human transferrin (rh-transferrin) is preferred for drug safety 
considerations. From research in monoclonal antibodies became clear that humanized 
proteins have better safety profile than non-humanized. The same for recombinant 
proteins versus purified ones.  
4. Iron metabolism in bacteria and human 
 The primary antimicrobial mechanism of action by transferrin is to sequester iron from 
the environment and starve the microbe of iron [19]. Below I will highlight just a few 
important aspects of iron metabolism, for detailed description major monographs [e.g. 40] 
should be consulted. 
 Iron is an essential element for all known forms of life. The biological activity of iron 
is due to its ability to accept or donate electrons while switching between its ferrous bivalent 
(Fe(II), Fe2+), ferric trivalent (Fe(III), Fe3+) and its ferryl tetravalent (Fe(IV), Fe4+) states, 
thereby functioning as a catalysing cofactor in various biochemical reactions [42]. In human 
systemic level of iron metabolism is mostly regulated by hepcidine (Fig. 1.2) . Hepcidin 1
induces the degradation of ferroportin, the only known cellular exporter of unbound iron in 
vertebrates, and prevent exit of iron from cells [41-42]. Thereby, increased expression of 
hepcidine reduces iron plasma level. Regulation of hepcidin expression goes mostly through 
SMAD signalling pathway [42]. 
 Cellular iron metabolism consists of three processes: intake, utilization and efflux. 
Transferrin is a key player in these processes (Fig. 1.3). Transferrin is formed by a single 
polypeptide chain containing 679 aminoacid residues and two N-glycosidic chains of complex 
type; the total molecular weight is calculated to be about 80,000 Da with 5.9% being 
carbohydrate. Under physiological conditions, transferrin is about 30% saturated with iron. 
Accordingly, 4 different forms of transferrin coexist in plasma in terms of their iron content 
[40]: 1) apotransferrin (without ferric ions); 2) monoferric transferrin (iron in the N-terminal 
domain); 3) monoferric transferrin (iron in the C-terminal domain); 4) diferric transferrin 
 Figures 1.2 and 1.3 reprinted with permission - Bart J. et al, 2017 - Nature Publishing Group, License number 1
4105860731520 from May 11th, 2017; reuse in a dissertation / thesis.
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(iron in the two binding sites). Monoferric or diferric transferrin is also generally known as 
holotransferrin.   
 Transferrin binds iron with very high affinity (Kd = 10-23M), which can vary 
depending on pH [41]. In healthy organism transferrin is never fully saturated with iron, and 
the unbound transferrin can rapidly take up iron excess as a result of e.g. hemolysis. [43].  
 The concentration of intracellular iron required for bacterial survival is equal to 10-6 
M.  However, in mammals, the concentration of free ionic iron is much lower at 10-22M [41]. 
The severe iron limitation in the host was commented upon by Colin Ratledge: «The 
acquisition of iron is possibly the major determinant as to whether a microorganism that finds 
itself within an animal is able to maintain itself therein.» [43]. Pathogenic bacteria developed 
Figure 1.2. Overview of systemic iron metabolism. HAMP is a gene encoded hepcidine, FPN - ferroportin 
[42].
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different mechanisms to sneak iron from host in order to survive in these iron limited 
environments. One possible solution utilized by Yersinia spp, Pseudomonas, Vibrio, 
Enterobacteriacae, etc., is producing siderophores - high affinity iron-binding proteins that 
remove iron from the host [43]. Siderophores physically capture iron from host proteins 
(transferrin and ferritin) due to their very high affinity to iron (ranged from Kd = 10-22M to 
Kd = 10-50M) [43]. Another strategy developed by bacteria (more common for Gram-
negatives) is direct contact of bacterial cell to host iron-transporting proteins, like transferrin 
Figure 1.3. Cellular metabolism of iron in humans. Abbreviations: Non-transferrin bound iron (NTBI); metal-
ion transporter 1 (DMT1), Zrt- and Irt-like protein 14,8 (ZIP14,8) ; six-transmembrane epithelial antigen of 
prostate (STEAP); transferrin receptor 1 (TFR1); scavenger receptor CD163; lipoprotein receptor-related 
protein 1 (LRP1); haem-responsive gene 1 protein homologue (HRG1); feline leukaemia virus subgroup C 
receptor-related protein 2 (FLVCR2); haem oxygenase 1 (HO1); Scavenger receptor class A member 5 
(SCARA5); labile iron pool (LIP); ferroportin (FPN); iron regulatory protein–iron-responsive element (IRP–
IRE); hypoxia-inducible factor–hypoxia response element (HIF–HRE); prolyl-4-hydroxylase (PHD). Adopted 
from [42].
Chapter 1. Literature Review P19
or heme. Bacteria can express specific transferrin-binding proteins, which stimulate the 
release of iron ion from transferrin while other proteins form a channel to transport it through 
membrane [43].   
5. Resuzurin-based cell viability assay 
 In this study we used resuzurin-based cell viability assay for conducting a time-kill 
assay in Acinetobacter baumannii. Resazurin is a redox indicator that can be used to monitor 
the number of viable cell [44]. Another name for resazurin - Alamar Blue stands for its color 
when dissolved in water. The main property of this indicator is to change its color when 
metabolically active cells are presented. The biochemical mechanism behind this is a 
conversion of oxidized for (resazurin) to reduced form (resofurin) by NADPH dehydrogenase 
or NADH dehydrogenase intracellularly (Fig. 1.4) [44].   
 A pink color is indicative of the formation of resofurin, therefore the change of color 
from deep blue to pink over time can be detected by eyes or using spectrophotometer with a 
560 nm excitation / 590 nm emission [44]. 
 Resazurin is not toxic for cells because it does not interfere with the pathways in the 
respiratory chain [46]. The resazurin reduction assay has been used for monitor cell 
proliferation and viability of eukaryotic cells [44]. For prokaryotic cells, resazurin has been 
used for many tests including antibiotic susceptibility testing [45]. 
 The resazurin reduction assay has numerous advantages such as: 
1. High sensitivity. It is slightly more sensitive than tetrazolium reduction assays [44] 
2. Scalability. The assay has been used in high-throughput screens. 
Figure 1.4. Biochemical reaction of resazurin reduction in cells. Adopted from [44].
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3. Cost-effectiveness. In one study [47] resazurin significantly reduced the cost of 
Mycobacterium tuberculosis susceptibility test up to $3 for each test.  
4. Longitudinal studies. Samples can be serially monitored over time.  
 Protocols about the usage of Alamar Blue highly dependent on tested cell type. In 
particular, volume and concentration of resazurin solution, time and conditions of incubation, 
plate reader settings can vary dramatically and should be optimized for each cell type. Thus, 
many protocols for Alamar Blue assay have been proposed, however, no protocol existed for 
the time-kill assay. The closest methodology was found in [49], where authors tested different 
antibacterial compounds against Human African Trypanosomiasis. The protocol we developed 
is described in detail in the «Methods» chapter.  
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Chapter 2. Materials and Methods 
Microbial strains and culture conditions 
 Two drug-susceptible and two drug-resistant strains of Acinetobacter baumannii and 
Klebsiella pneumonia (8 strains in total) were used in this study (Table 2.1). Overnight broth 
cultures were grown in Tryptic Soy Broth (TSB), and bacteria were subcultured in Mueller 
Hinton II broth (MH2) to obtain bacteria in log-phase growth. Culture media with a very low 
level of free iron is needed for assays involving transferrin and RPMI 1640 (Thermo Fisher 
Scientific, Cat# 11875085) was used. 
Antimicrobial compounds used 
 Apotransferrin human (Sigma-Aldrich cat # T1147), used for all experiments and 
heretofore referred to as transferrin, was generated by resuspending transferrin powder in 
Omni-Trace water (EMD Millipore Corporation, CAT# WX0003-6). Ciprofloxacin (Sigma-
Aldrich, Cat# 17850) and meropenem (APP Pharmaceuticals, Cat#350720) were made fresh 
for each experiment. Stock solutions of ciprofloxacin (5 mg/ml) were dissolved in 0.05M HCl 
OmniTrace Ultra Water (EMD, #WX0003-6). Meropenem was dissolved at a stock 
concentration of 5 mg/ml in RPMI 1640 (Thermo Fisher Scientific, Cat# 11875085). 
Table 2.1. Minimal inhibitory concentrations (MIC) for strains of Acinetobacter baumannii and Klebsiella 
pneumonia which were used in the study. Pink colour marks drug-resistant strains.
MIC (µg/mL)
Bacteria Strain Transferrin Ciprofloxacin Meropenem
A. baumannii
HUMC1 4 256 128
AB074 4 <1 <0.5
VA-AB21 2 <1 <0.5
UH118 8 128 64
K. pneumoniae
KPC-KP1 32 32 32
KPC-KP6 >512 32 16
KP-nPDR #3 128 0.03125 0.0625
KP-nPDR #4 8 0.03125 0.0625
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Resazurin-based time-kill assay  
 The time-kill assay for A. baumannii was done by the resazurin assay. Metabolism of 
resazurin by viable bacteria was used as a surrogate measurement for CFU enumeration [44]. 
The protocol can be found in the Supplementary Materials, S1.  
 Overnight cultures of the bacterium were grown in tryptic soy broth (TSB), then 
diluted 1:100 in Mueller Hinton II broth, and sub-cultured to an OD600 of 0.5. 1 mL of the 
bacteria was washed two times with RPMI 1640 (Thermo Fisher Scientific, Cat# 11875085) 
and resuspended in 1 mL of RPMI 1640. Then the bacteria were diluted with RPMI 1640 to a 
working concentration of 1*106 CFU/mL. The number of CFUs was confirmed by plating 
serial dilutions of bacteria on the TSA plates.  
 100 µL of bacteria were seeded into round bottom 96-well plates and 3-6 technical 
replicates were done for each experiment. There were 21 groups: 3 groups of transferrin alone 
in 3 different concentrations (1/3X, 1X, and 3X of its MIC); 4 groups of antibiotics alone 
(ciprofloxacin and meropenem in 1/3X and 1X MIC concentration each), 6 combo groups for 
ciprofloxacin, 6 combo groups for meropenem, a positive control without any drug, and a 
negative control without bacteria. 50 µL of drug was added to each well as needed and the 
final volume of each well was filled to 200 µL with RPMI. Edge rows were filled with 200 µL 
of PBS to minimize evaporation.  
 20 µL of 0.1% aqueous resazurin solution was added to each well and the plate was 
incubated at 37°C without shaking for 24 hours. After incubation fluorescence was measured 
(excitation 544 nm, emission 590 nm) at 0h, 1h, 2h, 4h, 6h, 8h, and 24 hours using the 
FLUOstar Omega plate reader (BMG LABTECH GmbH, Germany). The gain adjustment of 
fluorescence was was set up as 1000. 
 The reduction of resazurin was calculated using following equation [50]: 
where F is fluorescence in arbitrary units (AU) for any of experimental groups, Fneg 
fluorescence in AU in negative control group, Fpos is fluorescence in AU in positive control 
group. Thus, resazurin reduction rate (RRR) ranges from 0 to 1, where 0 is no fluorescence 
above internal fluorescence of media, and 1 is fluorescence equal to positive control, i.e. 
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maximum possible number of viable cells. The median and interquartile range of the RRR at 
each time point were plotted.  
 To evaluate the relationship between number of bacterial cells and resazurin 
fluorescence signal we built a standard curve. The number CFUs was estimated by measuring 
the OD600, (OD600 = 0.5 corresponds to 2*108 CFUs/mL). Serial 2-fold dilutions of broth 
culture, starting from 1*106 CFUs/mL, were prepared in 96-wells plate, then 20 µL of 0.1% 
aqueous resazurin solution was added to each well. Each dilution had at least 6 technical 
replicates. The bacterial inoculum (CFUs/mL) was confirmed by plating on TSA plates. 
Cultures were incubated without shaking at 37°C for 24 hours and then fluorescence was 
measured using the same settings as for time-kill assay. Using mathematical transformation, 
linear regression was built and R2 was calculated. Fluorescence values (in AU) were plotted 
against mathematical derivate of OD600. Thus, a standard curve was constructed for each 
strain and the range of the linear relationship was determined. The equation for CFUs number 
calculation was found, importantly that it should be used just within the range where variables 
appropriately fit the curve. 
Time-kill assay based on CFUs quantification 
 Time-kill assay for K. pneumonia was done by CFUs counting at four time intervals 
during 24 hours [53]. Protocol can be found in Supplementary materials, S2.  
 Culture preparation was the same as for resazurin-based time-kill assay.The 
experiment was set up in 10-mL tubes with 2 technical replicates for each experiment to a 
final volume of 2 mL. There were 7 groups: 3 groups of all drugs alone in 1 MIC 
concentration (transferrin, ciprofloxacin and meropenem); 2 combo groups: 1 MIC 
ciprofloxacin + 1 MIC transferrin, and 1 MIC meropenem + 1 MIC transferrin; 1 group of 
positive control with bacteria but without any drug; and 1 group of negative control without 
bacteria, with RPMI only. All tubes were incubated at 37 °C for 24 hours without shaking. 10 
µL culture aliquots were collected at each time point (i.e. 0, 1, 2, 6 and 24 h), and 10X serial 
dilutions were prepared in PBS. 100 µL from three different dilutions were plated at TSA 
plates in 3 technical replicates for each. Plates were incubated 37 °C for 24 h.  The numbers 
of colonies were counted and curve of killing was plotted. The median and interquartile range 
of CFUs number at each time point during 24 hours were plotted against time for each group. 
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Sub MIC 24 hrs passage and selection of antibiotic resistant mutants 
 K. pneumoniae KP-nPDR#3 and KP-nPDR#4 were passaged for 24 hours in sub-MIC 
concentrations of ciprofloxacin and meropenem with and without transferrin. 7 groups were 
included in experiment layout: 3 groups of drugs alone (ciprofloxacin, meropenem, and 
transferrin), 2 combo groups, a as positive control, and a negative control. Transferrin was 
used at a concentration of 750 µg/mL. Antibiotics were added at a concentration equal to 1/3x 
the MIC. A high bacterial inoculum (108 CFUs/mL) was used to increase the sensitivity of 
mutant detection. Bacteria were cultured in 2 mL of RPMI in 10 mL conical tubes and 
incubated at 37°C / 200 rpm / 24 hrs. Bacteria were then concentrated by centrifugation and 
the total CFU was determined by plating serial dilutions on non-selective TSA plates. The 
remaining culture was plated equally on 2 plates containing 16 µg/mL of antibiotic (the full 
protocol is available at Supplementary materials, S7). TSA plates were incubated 37°C / 
24 hrs. Colonies in all plates were counted, and the proportion of antibiotic-resistant bacteria 
in bacterial population was calculated. The experiment was repeated 3 times.  
Sub MIC serial 20 days passage and selection of antibiotic resistant mutants  
 Antibioitc susceptible strains of A. baumannii and K. pneumoniae were passaged for 
20 days ciprofloxacin and meropenem with and without transferrin. Two control groups with 
transferrin only or bacteria only were passaged as well. The starting concentration of 
antibiotics were equal to ¼x MIC and transferrin was equal to 1X MIC. The cultures were 
grown in 1 mL of RPMI in 24-well plates at 37°C without shaking. After each 24-hour time 
period, 10 µL of the passaged culture were transferred to a new plate with the same treatment 
condition. At days 5, 10, 15 and 20 the culture from each well was plated on the two selective 
agar plates containing 2X and 10X the antibiotic concentration that was used for passaging. 
Bacteria was also plated on nonselective agar to check for the presence of viable bacteria as a 
control. Control groups were plated on both ciprofloxacin and meropenem selective plates. 
Possible bacterial contamination was checked by MALDI-TOF/TOF mass spectrometry 
(“MALDI Biotyper”, Bruker, USA). The concentration of antibiotics for the next step of 
passage was defined as the concentration in the selective plate that presented 100 or more 
CFUs. The concentration of transferrin was increased 2x for all groups at each step. Glycerol 
stocks of the strains were made every 5 days. After 20 days all groups were plated on the 
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selective plates with 16 µg/mL of ciprofloxacin or meropenem as well as on nonselective 
plate with serial dilutions to define inoculum plated. 
Acquired resistance to transferrin 
 K. pneumonia strain KP-nPDR#3 was passaged for 15 days in 1000 µg/mL of 
transferrin, which is 7.8x times higher than the starting transferrin MIC (128 µg/mL). Bacteria 
was cultured in 1 mL of RPMI and 10 µL of culture was passaged daily to a fresh culture 
containing transferrin. Serial passage was continued for 15 days and glycerol stocks were 
stored. After passaging cells for 15 days in the presence of transferrin, the bacteria were then 
passaged for 5 days in the absence of in  TSB media without transferrin. Sensitivity to 
transferrin was determined for the 3 groups by MIC assay: parental strain, bacteria from the 
day 15th of passaging with transferrin 1000 µg/mL, and bacteria from day 5 of passaging in 
TSB.  
Single drug MIC 
 Clinical & Laboratory Standards Institute (CLSI) guidelines recommends to perform 
MIC assay in Mueller Hinton II (MH2) Broth [61]. However, since high levels of iron will 
affect transferrin, the MIC assay was completed in RPMI 1640 (Thermo Fisher Scientific, 
Cat# 11875085), which does not have iron in the basal formulation. 
 Overnight cultures of the bacterium grown in tryptic soy broth (TSB) were diluted 
1:100 into MH2 broth and sub-cultured until the OD600 reaches 0.5. Bacteria were centrifuged 
at 6000×g for 5 minutes and the pellet was washed 3 times with RPMI. The washed pellet was 
resuspended in the original volume of RPMI. Bacteria were diluted to a working 
concentration of 1×106 CFU/mL. The bacterial density was confirmed by plating serial 
dilution on tryptic soy agar (TSA) plates and counting CFUs. 
 MIC assays were done in standard 96-well round bottom (U-shaped) plates. Drug 
dilutions were done by serial 2x dilutions across the columns of the plate. Bacteria alone and 
media only wells were included as positive and negative controls respectively. 100 µL of 
1×106 CFU/mL bacteria culture was added to the necessary wells. Plates were incubated for 
24 hours at 37°C. We defined the transferrin MIC value as the lowest concentration of 
transferrin that shows at least 90% reduction in visible pellet size when compared to the 
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bacteria only positive control. The number of CFUs at the initial culture was confirmed by 
plating serial dilutions of bacteria on the TSA plates. 
Macrophage phagocytosis assay 
 The assay was done as described in [72, 73]. The full protocol is available at 
Supplementary materials, S9. A. baumannii AB074 ciprofloxacin passaged strain (day 15 of 
the 20-day passage experiment) was tested for in vitro virulence. RAW264.7 cells, a murine 
macrophage cell line, were seeded onto glass coverslips in 1 mL of Dulbecco’s modified 
Eagle medium with 10% fetal bovine serum (heat-inactivated) supplemented with 100U of 
interferon-γ in 12-well tissue culture plates. The cells were cultured overnight in a humidified 
incubator at 37°C with 5% carbon dioxide. 106 CFUs of bacteria were added on top of the 
coverslip in 1 mL of HBSS with 20% complement-active CD-1 mouse serum (Innovative 
Research). The plates were briefly centrifuged at 250 g and incubated for 1 hour at 37°C with 
5% carbon dioxide. Then wells were washed to remove the bacteria floating in the media. 
Macrophages were fixed with 100% methanol, and stained using Hema-3 Manual Stains 
(Thermo Fisher Scientific, Cat#22-122911). The number of CFUs at the initial bacterial 
culture was confirmed by plating serial dilutions of bacteria on the TSA plates. Zeiss 
AxioImager (Carl ZEISS AG, Germany) microscope was used for visualization of 
macrophages. Images that included ≥ 5 visible macrophages within the frame were analyzed 
using the ImagePro software at 1000x magnification, and the picture of each appropriate zone 
was taken. The number of bacteria inside the macrophages was counted, and the median and 
interquartile range were calculated. 
In vivo study 
 C3H/FeJ (Jackson Laboratory (JAX), USA) mice 8-11 weeks old were infected 
intravenously by tail-vein injection with 2*107 CFUs/mL (LD100 dose) of K. pneumonia KP-
nPDR#3 and treated with 3 different doses of ciprofloxacin: 50, 10, and 3 mg/kg/day. 
Antibiotic was administered intravenously by tail-vein injection twice a day for 4 days after 
infection. First injection was done right after the infection. The time to moribund condition 
was monitored over the course of 7 days. Moribund condition, defined as inability to 
ambulate after tactile stimulus, is used as a humane endpoint because death is not an 
acceptable endpoint under NIH/IACUC rules. 5 mice per group were used. All animal 
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experiments were approved by the Institutional Committee on the Use and Care of Animals at 
the University of Southern California, Keck School of Medicine, following the National 
Institutes of Health guidelines for animal housing and care. 
Statistical analysis 
 Data analysis was performed using R statistical software and MS Excel. Normally 
distributed variables were analysed by ANOVA test. The correction for multiple comparisons 
was done if needed by Tukey's HSD (honest significant difference) test. For data distributed 
in other than normal way nonparametric statistical tests, like Mann-Whitney U Test were 
applied. Survival curves were compared by nonparametric log rank test. P value was 
considered as significant when < 0.05. 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Chapter 3. Results 
 The impact of adjunctive transferrin in combination with antibacterial agents against 
Gram-negative bacteria was tested in vivo and in vitro. Transferrin alone, or in combination 
with either ciprofloxacin or meropenem, was studied in the antibiotic-susceptible and resistant 
strains of A. baumannii and K. pneumoniae. Those two particular antibiotics were picked as 
good exemplars of antibiotics commonly used in clinical practice but with two distinct 
mechanisms of action. 
1. Transferrin: Synergy and Antagonism 
  It was hypothesized that transferrin would act synergistically, or improve the efficacy, 
with antibiotics. 
 There are two possible antimicrobial interactions, synergy and antagonism. We used 2 
different methods to assess the antimicrobial interactions in vitro. First, the checkerboard 
technique, is a modified version of the MIC assay that measures most visible growth 
inhibition. Briefly, this method involves the combinatorial addition of 2 drugs in a 96-well 
plate and determining the MIC. The MIC of the single drugs alone, and the drug combination 
are used to calculate the fractional inhibitory concentration index (FIC) [48]. FIC is calculated 
as ΣFIC = FICA + FICB = (CA/MICA) + (CB/MICB), where MICA and MICB are the MICs of 
drugs A and B alone, and CA and CB are the concentrations of the drugs in combination [74]. 
The second method measures the antibiotics interaction by quantifying microbial killing over 
time and developing and time-kill plot [48]. The time-kill assay is more sensitive as compared 
to the MIC because the number of viable bacteria are quantified by plating serial dilutions on 
agar plates. Thus, the time-kill assay as validated and sensitive analysis was chosen to test the 
hypothesis and define interactions between transferrin and antibiotics.  
 Classical definition of synergistic antimicrobial interaction in time-kill assay reads that 
synergy is when in combination there is more than 2 log10 decrease in CFU number as 
compared to use of a single drug [48]. Previous experiments (unpublished) used the 
checkerboard technique and found no interaction between transferrin and antibiotics 
(ciprofloxacin and meropenem) in 24 hours. The aim of our experiment was to reveal possible 
hidden interaction resulted in different kinetic of killing in the presence of transferrin during 
24 hours time period. 
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 In time-kill assays for A. baumannii and K. pneumoniae we used two different 
protocols: with and without resazurin (see Methods and Supplementary materials, S1-2). As 
it was described in literature review section, resazurin-based time-kill assay has a number of 
advantages. Resazurin assay allows high-throughput analysis, as compared to a traditional 
time-kill assay that requires plating serial dilutions of bacteria on agar plates. However, the 
resazurin assay needs to be validated when developing a new experimental protocol and may 
not work for all organisms/methods.  Consequently we were only able to establish a feasible 
protocol for A. baumannii  (see Supplementary materials, S1). The incubation time for 
resazurin metabolism by K. pneumonia turned out to be unacceptable for normal workflow in 
the lab. 
 The raw data, fluorescence measurements, are readily available at https://doi.org/
10.5281/zenodo.571838 (open access for A. baumannii AB074 strain only). The R-script for 
data analysis is available at https://doi.org/10.5281/zenodo.572307. 
 Although the definition of synergy is well-established for CFU-based time-kill assay, 
there is no such definition for resazurin-based assay. Therefore in this study, we suggested 
defining synergy or antagonism as a statistically significant difference in RRR between each 
individual drug alone and drug combination groups. Figure 3.1 demonstrates typical case (for 
all cases see Supplementary materials, S3-4) which provides evidence of the lack of 
interactions between transferrin and antibiotic. Looking at 1/3X MIC dose of all drugs, we 
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Figure 3.1. Resazurin reduction rate (RRR) over 24 hours for A. baumannii HUMC1 when treated with 1/3 
MIC of meropenem alone or in combination with 3 different concentration of transferrin (1/3, 1 and 3 MIC) 
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can compare transferrin alone (pink line with triangles), meropenem alone (black line), and 
their combination (blue line with triangles). There are no significant differences in RRR 
between groups. Thus, it can be concluded that there is no in vitro interaction between 
transferrin and meropenem when given given drug concentration in A. baumannii HUMC1.  
 The same pattern was demonstrated in CFU-based time-kill assay for K. pneumonia 
(Fig 3.2). Using classical definition of synergy [48], we found that there is no synergistic 
interactions between transferrin and antibiotics in 24 hours. In this particular case there is a 
trend towards antagonism between transferrin and meropenem, although it is not statistically 
significant. 
 Remarkably, synergy was observed in two cases out of 16 tested combinations. The 
first one is combination of ciprofloxacin (1/3 MIC) and transferrin (1/3 MIC) in A. baumannii 
UH118 (Fig. 3.3), the second one is combination of ciprofloxacin (1 MIC) and transferrin (1 
MIC) in A. baumannii HUMC1. Figures 3.3 shows statistically significant difference between 
ciprofloxacin alone (black line) and combination (blue line with triangles), as well as between 
transferrin alone (pink line with triangles) and combination (blue line with triangles). Both 
synergistic interactions took place in drug-resistant strains of A. baumannii. Antagonism was 
not observed.  
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Figure 3.2. CFU-based time-kill assay for K. pneumonia when treated with each drug alone (ciprofloxacin, 
meropenem, transferrin) or with combination of 1 MIC of transferrin with either 1 MIC of ciprofloxacin or 1 
MIC of meropenem
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2. Transferrin Increases the Antibacterial Effect of Meropenem and 
Ciprofloxacin In Vitro 
 The second goal of the time-kill assay was to clarify whether transferrin increases the 
antibiotic’s killing rate over time. To address this question we compared RRR of antibiotic 
alone with RRR of three combo groups with different concentrations of transferrin.  
There was a positive benefit for the addition of transferrin for at least one tested drug 
combinations for 3 out of 4 strain. A decrease in the RRR was observed in a dose-dependent 
manner when transferrin was added to antibiotics (ciprofloxacin and meropenem) as 
compared to antibiotic only group.  
 Figure 3.4 represents a good example of transferrin’s benefits in A. baumannii 
AB074. The combination of 1/3 MIC of meropenem with 1 MIC of transferrin (blue line with 
dots) causes a decrease in the RRR by more than 2X as compared to 1/3 MIC of meropenem 
alone (black line) (p < 0.01), while there was no difference between 1 MIC of transferrin 
alone and the same combination (Fig. 3.4). Increasing the amount of transferrin added to the 
culture results in a dose dependent improvement. 
 Thus, we found that transferrin increases the antibacterial killing effect of 
ciprofloxacin and meropenem in vitro against tested pathogens. It was especially relevant 
when bacteria were treated with suboptimal concentrations (1/3 MIC) of antibiotics. 7 out of 
16 cases (Supplementary materials, S3, Figures E, F;  S4, Figures A, B, C, E, F) 
Figure 3.3. Resazurin reduction rate (RRR) over 24 hours for A. baumannii UH118 when treated with 1/3 
MIC of ciprofloxacin alone or in combination with 3 different concentration of transferrin (1/3, 1 and 3 MIC) 
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demonstrated advantages of the drug combination. The finding is consistent with previously 
reported data, such as in [51] where transferrin and lactoferrin were shown to improve the 
antibacterial activity of subinhibitory concentration of rifampin against Gram-negative 
bacteria. 
3. Resazurin-Based Time-Kill Assay in A. baumannii 
 It was important to demonstrate that the fluorescence signal is correlated with changes 
in CFU. Such correlation between CFUs and fluorescence over time was established for A. 
baumannii. Figure 3.5 shows that fluorescence intensity is proportional to CFU. Aliquots 
from the same culture were used to measure fluorescence and also for CFU enumeration by 
plating serial dilutions on agar plates to determine the CFU at each time point. Resazurin 
reduction was read after 24 hours of incubation with 0,1% resazurin in 37C. Experiment 
provided an evidence that the fluorescence correlates with CFU. Pearson correlation 
coefficient is equal to +0.49, indicating a moderate positive correlation between two sets of 
variables. 
 Standard curves of fluorescence were done for all tested strains based on serial 
dilutions. R-script for mathematical transformation and curve generation is stored at https://
doi.org/10.5281/zenodo.572328. 
 It has been revealed that each strain has a unique relationship between fluorescence 
and number of cells. However, all of them demonstrated acceptable range of linearity. Figure 
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3.6 represents and example of standard curve (for all standard curves see Supplementary 
materials, S5) with calculated R2 and equation of linear regression. Linear regression with R2 
= 0.7 and above was considered as acceptable. The equation for CFUs number calculation 
was found, importantly that it should be used just within the range where variables 
appropriately fit the curve. 
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Figure 3.5. Correlation between number of CFUs and Fluorescence (in AU) for A. baumannii HUMC1 treated 
with 1 MIC of ciprofloxacin for 24 hours or without any drugs.
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4. Transferrin Has Bacteriostatic Mode of Action 
 Antibiotics can be broadly categorized as having a bactericidal and bacteriostatic 
mode of action. Bactericidal antibiotics kill the bacteria while bacteriostatic antibiotics inhibit 
the growth of bacteria. Despite the intuitively understandable idea behind the concept, it was 
argued already in 1957 that the classification is artificial to some extent, and that there is no 
pure examples of each group [52-53]. However, for in vitro research the assigning of the drug 
into one of two categories provides valuable information on the antimicrobial potential. 
 In accordance with the widely-accepted definition, the bacteriostatic action is 
determined when less than a 1000-fold reduction in CFUs in treated group compared to 
growth control appeared by the end of incubation [54]. In this study, we were able to evaluate 
bacteriostatic/bactericidal activity only in the CFU-based time-kill assay. 
 Ciprofloxacin and meropenem significantly reduce the number of CFUs during the 
first 6 hours of exposure, whereas transferrin doesn’t prevent bacterial growth during that 
time (Fig.3.2). According to the definition of static antibacterial mode, number of CFUs was 
compared between 1 MIC of transferrin group and no drug (positive control) group at 24 
hours time point. For most cases the difference between group didn’t exceed 1000-fold, 
therefore transferrin was considered as bacteriostatic agent. The result is consistent with 
earlier finds demonstrating that transferrin has bacteriostatic mode of action against S. aureus, 
A. baumannii, and C. albicans in time-kill assay [20].  
 There is not a clear clinical benefit of utilizing a bactericidal vs bacteriostatic 
antibiotic. A recent meta-analysis that included 33 clinical trials was unable to find a benefit 
in clinical cure rates or mortality rates when comparing bactericidal and bacteriostatic 
antibiotic therapy [55]. Authors concluded that “the categorization of antibiotics into 
bacteriostatic and bactericidal is unlikely to be relevant in clinical practice” [55]. 
5. Transferrin Decreases the Emergence of Antibiotic Resistance in 24 hours 
 In this study we evaluated the resistant phenotype frequency. It was defined as the 
proportion of mutant (antibiotic-resistant) bacteria present in a culture after 24 hours of 
incubation with antibiotic [58]. It should be noted here that mutation frequency doesn’t 
represent the intrinsic property of an antibiotic, and it is not the same as mutation rate. A 
mutation rate reflects the probability of a mutation arising per one cell division at the presence 
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of given antibiotic [57]. “The relationship between mutation frequency and the rate at which 
mutations occur is uncertain.” [58]. 
 Previous research demonstrated that the resistance frequency is highly variable and 
depends on many factors. A list of such factors increasing antibiotic resistance mutation 
frequency, includes low antibiotic concentrations, short time of antibiotic exposure, bacteria 
being under the stress conditions, slow killing ability of the antibiotic, etc. [57]. In addition, 
the different concentrations of the same antibiotic select for different bacterial populations 
and consequently for different mutations (Fig. 3.7) , although the phenotype (ability to grow 2
on the selective media) is the same. In our research we used subinhibitory concentration of 
antibiotics. 
 High inoculum of drug-susceptible bacteria were incubated with ciprofloxacin or 
meropenem in concentration equal to 1/3x MIC for 24 hours. Bacteria were selected against 
either antibiotic alone or in combination with transferrin 750 µg/mL (the full protocol is 
available at Supplementary materials, S7). After 24 hours all groups of bacteria were tested 
on selective agar supplemented with 16 µg/mL of drug, the clinical cutoff for ciprofloxacin 
and meropenem resistance. The absolute number of colonies and the the proportion of 
mutants per 108 bacterial cells are recorded in Supplementary materials, S6. R-script to  
 Figures 3.7 reprinted with permission - American Society for Microbiology - Journals, order number 2
501269010 from May 11th, 2017; reuse in a dissertation / thesis.
Figure 3.7. Structure of bacterial populations selected at different antibiotic concentrations. From [57]. 
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perform data analysis is available at https://doi.org/10.5281/zenodo.572978. 
 We revealed that transferrin significantly decreases the emergence of ciprofloxacin 
resistant mutants in Klebsella pneumonia KP-nPDR#3 and KP-nPDR#4 in 24 hours (Fig. 
3.8). A similar tendency was observed for meropenem mutants, although the difference across 
the groups was found to be not statistically significant (Fig. 3.9). 
 The overall result is consistent with previously reported data about the frequency of 
antibiotic-resistant mutant emergence. For example, it was found in 1997 that in the Gram-
negative bacterium P. aeruginosa the frequency of resistance against quinolones varied from 
1,2*10-6 to  4,3*10-10 depending on the drug and its concentration: the greater the antibiotic 
Figure 3.8. Selection for mutants resistant to ciprofloxacin after 24 hours of antibiotic exposure (in 
subinhibitory concentrations = 1/3 MIC) with or without 750 µg/mL of transferrin. K. pneumonia KP-nPDR#3 
and KP-nPDR#4. Statistically significant difference between groups marked by the lines above the columns 
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concentration, the lower the frequency of antibiotic-resistant mutants [56]. Our results are also 
within that reported range as in [56] (Table 3.1). 
  
 Remarkably, the mutations frequency was significantly different across the antibiotics 
as well as bacterial strains. Figures 3.8 and 3.9 show that K. pneumonia KP-nPDR#3 was 
able to develop resistant mutants to both antibiotics in 2-10 times greater frequency as KP-
nPDR#4. Mutations providing resistance to meropenem occurred at about 10 times less often 
than mutations to ciprofloxacin for both tested strains. 
6. Transferrin Reduce the Rate of Antibiotic Resistance Development 
 We tested four drug-susceptible strains of K. pneumonia and A. baumannii (two strains 
of each species) in 20-days antibiotic passaging experiment. The passage was started from 
1/4x MIC of antibiotics concentration and every 5 days the concentration was increased up to 
maximum concentration which bacteria are able to tolerate. Bacteria were treated with 
ciprofloxacin or meropenem alone or in combination with transferrin. The concentration of 
transferrin was also increased at each step. The step-wise increase of antibiotic was done  if 
bacteria could tolerate it. Data about drugs concentration changes over time for each group 
were collected and analysed. R-script for data analysis is at https://doi.org/10.5281/zenodo.
573292 .  
 Figure 3.10 demonstrates the dynamics of both ciprofloxacin and meropenem 
concentrations with and without transferrin in A. baumannii VA-AB21 (A) and K. pneumonia 
KP-nPDR#4 (B) strains. It is seen from the graph that the rate of antibiotic resistance 
selection was faster in antibiotic alone groups as compared to combo groups. For both strains 
the difference was statistically significant. The trend is similar across the species and the rest 
of the dynamics graphs are available at Supplementary materials, S8. 
Table 3.1. The frequency of spontaneous mutations against ciprofloxacin and meropenem 
emerged within 24 hours in K. pneumonia KP-nPDR#3 and KP-nPDR#4.
Ciprofloxacin Meropenem
KP-nPDR#3 1,142E-08 2,51E-09
KP-nPDR#4 9,1E-10 1E-10
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  By 20 days Acinetobacter strains have overcome the drug susceptibility cutoff and 
could be considered as drug resistant (for more evidence single drug MIC assay is required). 
However, both Klebsiella strains remained below than given cutoff.  
 The next step of this experiment is determine the antimicrobial susceptibility profile 
against antibiotics not used in this study. The strains from the last (20th) day of the serial 
passaging will be tested for drug susceptibility using Trek GNX3F kit [60]. This test is based 
on MIC assay and checks MIC for 20 antibiotics against Acinetobacter or 21 drugs for 
Klebsiella. This test will help characterize if the addition of transferrin will help prevent the 
● ● ● ● ●
● ● ● ● ●
● ● ● ● ●
● ● ● ● ●
● ● ● ● ● ● ● ● ● ●
● ● ● ● ●
● ● ● ● ●
● ● ● ● ●
● ● ● ● ●Susceptibility cutoff
10−2
10−1
100
101
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Days
An
tib
iot
ic 
co
nc
en
tra
tio
n
Treatment groups
●
●
●
●
Ciprofloxacin
Ciprofloxacin + transferrin
Meropenem
Meropenem + transferrin
VA−AB21
Figure 3.10. The dynamics of antibiotics concentration (in S/mL) in 20 days passage with antibiotics with or 
without transferrin; A. baumannii VA-AB21 (A) and K. pneumonia KP-nPDR#4 (B).
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emergence of antibiotic-resistant mutants for antibiotics that were not included in the initial 
therapy. It is important because A. baumanni has a significant degree of intrinsic resistance to 
many antibiotics [59] and high potential to acquire resistant mutations, thus, a therapy of 
Acinetobacter infection is a challenge and any interventions which can decrease of new 
antibiotic resistance formation would be helpful. 
7.  Serial Passage of A. baumannii AB074 with Ciprofloxacin Increases its 
Virulence In Vitro 
 A. baumannii AB074 passaged in ciprofloxacin for 15 days, had increased its tolerance 
to ciprofloxacin 20x (from 0.25 to 5 µg/mL for sub MIC passaging) and was now drug-
resistant.  
 It is a generally believed hypothesis that antibiotic resistance and virulence correlate 
negatively. Basically, the decrease of virulence is considered as the trade-off for increased 
antibiotic resistance [69]. However, some studies don’t find any trade-offs between resistance 
and virulence [70]. 
 In vitro virulence phenotype was evaluated in a macrophage uptake assay (see the full 
protocol at Supplementary materials, S9). The results of  the assay as images from 
microscope are stored at https://doi.org/10.5281/zenodo.573369. Figure 3.11 shows an 
example of a typical microscopy images of bacteria phagocytosed by murine macrophages, 
and the number of bacteria inside the macrophage cells are noticeably different between 
No drug Ciprofloxacin
Figure 3.11. Image of light microscopy at x1000; murine macrophages in cell culture; uptake of  A. baumannii 
AB074 which was passaged for 15 days without drugs or in the presence of ciprofloxacin; hematoxylin-eosin 
staining
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groups. Thus, we found that the macrophage uptake of bacteria is significantly lower when 
bacteria treated by ciprofloxacin for 15 days – the median uptake was 29.25 versus 2.5 
bacteria per macrophage respectively, p > 0.05. 
 This finding can be considered as in vitro evidence of the increased virulence, to 
confirm the high virulence in vivo study is required. 
8. Transferrin Prevents the Emergence of Highly Virulent Strain of A. 
baumannii In Vitro 
 In macrophage phagocytosis assay we compared 6 groups of A. baumannii AB074 
strain, which were exposed to either drugs alone (transferrin, meropenem, ciprofloxacin) or to 
the drug combinations for 15 days. At the Figure 3.12 representative microscopic images of 
phagocytosis are demonstrated to show the evidently difference in the number of bacteria 
inside the macrophages across the groups. The graph is presented at Figure 3.13. We revealed 
that the macrophage uptake is significantly higher in the ciprofloxacin + transferrin combo 
group compared to ciprofloxacin only group (p > 0.05). Whereas the combo group is similar 
to transferrin only group and control group without any drug. The differences within the 
groups treated with meropenem as well as between them and no drug control were not 
statistically significant. 
 Thus, the addition of transferrin prevented the formation of highly virulent phenotype 
of A. baumannii AB074 stimulated by passaging with ciprofloxacin.  
Transferrin only Ciprofloxacin only Ciprofloxacin + transferrin
Figure 3.12. Images of light microscopy at x1000; murine macrophages in cell culture; uptake of  A. 
baumannii AB074 which was passaged for 15 days with either transferrin or ciprofloxacin or in their 
combinations; hematoxylin-eosin staining
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9. The Acquired Resistance to Transferrin Is Likely To Be Non-heritable 
 It was hypothesized that the acquired resistance to transferrin is due to changes in the 
regulation of gene expression, and doesn’t involve changes to the bacterial chromosome (gene 
mutations or the acquisition of a resistance gene), thus it will be non-heritable. 
 The strain of Klebsiella pneumonia KP-nPDR#3 had become highly resistant to 
transferrin during 5 days of passaging with increased concentration (2-4 times higher than 
MIC) of transferrin (initial MIC for transferrin was 128 µg/mL). For the next 15 days it was 
passaged with the highest acceptable amount of transferrin, 1000 µg/mL (higher 
concentrations are likely clinically irrelevant and therefore not investigated). The bacteria 
were able to grow at this concentration of transferrin and no growth deficiency was observed 
when comparing growth in the absence of transferrin. To test the hypothesis that resistance is 
phenotypic and non-heritable, the bacteria were passaged in TSB without transferrin for 5 
days. 
 Using standard single drug protocol, MIC assay was run for 3 groups of bacteria: 
parental strain, bacteria from the day 15th of passaging with 1000 µg/mL of transferrin, and 
bacteria from day 5th of passaging in TSB. The result is presented at Figure 3.14.  
 Notably, the MIC was the same across all 3 tested groups. Even the bacteria passaged 
in 1000 µg/mL of transferrin for 15 days demonstrated MIC which is almost 8 times lower 
p > 
Figure 3.13. Phagocytosis of A. baumannii AB074 by murine macrophages. The median of the number of 
bacteria per macrophage (+/-Q25, Q75) in 6 groups of treatment. The treatment was applied to the bacteria for 
15 days. Statistically significant difference between groups marked by the line above the columns.
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than 1000 µg/mL. Transferrin MIC for all groups came out to be the same as initial one. The 
most reasonable explanation of this phenomena is that resistance to transferrin was lost during 
overnight culturing without transferrin. A follow up experiment is needed in which the 
transferrin resistant passaged strain is cultured in the presence of transferrin during the 
overnight passage as well. This scheme should allow for growth of the transferrin tolerant 
strain in all transferrin conditions.   
 Eventually, the loss of resistance took place during the experiment. Thus, the 
resistance to transferrin is more likely to be non-heritable, however further study is required 
to find more clear evidence of this. 
10.  Subtherapeutic Dose of Ciprofloxacin Was Established in C3H/FeJ 
Mice 
 The behavior of drugs is different in vitro and in physiological conditions of complex 
organism, thus it is required to translate the findings from in vitro assay to animal models to 
confirm them. The overall goal of in vivo experiments is to demonstrate the efficacy and 
prevention of resistance of adjunctive transferrin therapy in animals in order to transfer this 
therapy to the clinic. It was hypothesised that transferrin can improve patient care in two 
problematic clinical situations. The first situation: a patient has an infection caused by drug-
resistant bacteria and adjunctive transferrin therapy will restore efficacy of the antibiotics that 
Parental strain
Bacteria, passaged in 
1 0 0 0 µ g / m L o f 
transferrin for 15 days
Bacteria, passaged in 
1 0 0 0 µ g / m L o f 
transferrin for 15 days 
followed by passaging 
in TSB for 5 days
Transferrin serial dilutions, µg/mL
Figure 3.14. Transferrin MIC assay for 3 different groups of K. pneumonia KP-nPDR#3. Pink line marks the 
resulted transferrin MIC, which is equal 125 µg/mL and the same for all groups.
Chapter 3. Results P43
would otherwise fail as a single-drug therapy. The second situation: a patient has an infection 
of a drug-susceptible bacteria treating by suboptimal dose of antibiotics, and adjunctive 
transferrin therapy helps prevent the subsequent emergence of an antibiotic-resistant 
pathogen. The ability to decrease the emergence of antibiotic resistance could have short-term 
and long-term benefits. It will help to preserve the efficacy of the antibiotics in use, and also it 
will prevent the spread of resistant bacteria that would create a burden for the healthcare 
system. In this study we addressed the second clinical problem. 
 We tested the susceptible strain of K. pneumonia KP-nPDR#3 and ciprofloxacin as a 
treatment. We chose the last based on in vitro results: transferrin decreased ciprofloxacin 
resistance emergence when applied together with ciprofloxacin for 24 hours. The first step of 
the study was to define the subtherapeutic dose of ciprofloxacin. To adjust the subtherapeutic 
dose we should first understand the therapeutic dose.  
 Previous studies reported that the therapeutic dose of ciprofloxacin varies in different 
animals and bacterial strains from 10 to 200 mg/kg/day for susceptible strains (MIC up to 1 
µg/mL) [63]. One study even shows that 50% protective dose of ciprofloxacin is 2-2.8 mg/kg 
after subcutaneous injection [62]. It was suggested that the AUC:MIC ratio is the most 
predictive parameter for outcome in treatment with quinolones against murine pathogen 
Figure 3.15. A: Relationship between ratio of free drug area under the concentration-time curve at 24 h to the 
MIC for 6 quinolones (ciprofloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and sitafloxacin) 
and survival in immunocompetent mice infected with Streptococcus pneumoniae [65]. B: The change in the 
number of CFU/mL at 24 hours when treated with 3 different quinolons (ciprofloxacin, levofloxacin and 
moxifloxacin) in different concentrations (unpublished).
B
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infection [64]. To reach 100% survival this ration should be around 100 ([65], and Figure 
3.15 A), however we aimed to rescue just 20-25% of the mice. Thus, we found that the 
AUC:MIC ratio equal to 10 is acceptable for 20-30% of mice to survive, as it was shown in 
[65] (Figure 3.15 A), and in Figure 3.15 B shown the corresponding amount of CFU under 
the different AUC:MIC ratio.  
 The in vitro ciprofloxacin MIC for K. pneumonia KP-nPDR#3 strain is very low 
(0.03125 µg/mL), but the exact AUC for ciprofloxacin in this murine strain is not defined. We 
can roughly estimate it based on literature data. It was found that in mice the dose 25 mg/kg 
produces AUC = 9.1 µg•hr/mL and pharmacokinetics of ciprofloxacin is linear within the 
range 10-80 mg/kg/day [66]. Veterinarians recommend to use ciprofloxacin at the dose 10 mg/
kg to treat infections in mice [67]. Recommended human dose is 15-20 mg/kg/day, and it’s 
able to produces AUC up to 31.6 µg•hr/mL [68].  
 Based on information described above we assumed that the therapeutic dose of 
ciprofloxacin in our study should be 50 mg/kg/day (AUC:MIC ratio is higher than 100) and 
10 and 3 mg/kg/day should be considered as potential subtherapeutic meaning that such dose 
can rescue only 20-30% of mice.  
 C3H/FeJ mice were infected with 2*107 CFUs/mL (LD100 dose) of K. pneumonia 
KP-nPDR#3 and treated with 3 different doses of ciprofloxacin: 50, 10, and 3 mg/kg. The 
control group where mice were treated with placebo was done as a control. Survival curves 
for all groups are presented at Figure 3.16. Thus, we found that the subtherapeutic dose of 
ciprofloxacin which allows to survive for 2/5 mice during 7 days post-infection is 3 mg/kg/
day. Further study is required to test the hypotheses.  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Figure 3.16. 7 days survival curves for C3H/FeJ mice infected with 2*107 CFUs/mL of K. pneumonia KP-
nPDR#3 and treated with ciprofloxacin in 50, 10, or 3 mg/kg or placebo.
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Chapter 4. Conclusion 
 This study addresses the important problem of antibiotic resistance among clinically 
significant Gram-negative pathogens.  
 In time-kill assay transferrin generally didn’t interact with ciprofloxacin or 
meropenem - neither synergy nor antagonism were observed. However, the addition of 
transferrin improved the effectiveness of the antibiotic killing, especially when it was used in 
high doses. There are some possible explanations. First, the bacteria under iron starvation 
conditions have a lower multiplication rate, so the number of live bacteria to be killed by 
antibiotic is less than in the iron-rich environment. Second, the bacteria become more 
sensitive to antibiotics under iron starvation conditions. The exact mechanism of this remains 
unclear. The mechanism of transferrin action was defined as bacteriostatic. 
 In 24 hours transferrin was able to reduce the emergence of resistance to ciprofloxacin 
by decreasing the frequency of resistant phenotype occurrence. A similar trend was found for 
meropenem. Although it was reported that starvation, in general, can increase the mutation 
rate, the molecular mechanism seems to be different for iron starvation In addition, transferrin 
can slow down the formation of antibiotic resistance during 20 days. 
 We found that the exposure to ciprofloxacin for 15 days leads to the occurrence of the 
highly virulent phenotype of A. baumannii AB074, which can be prevented by the addition of 
transferrin while incubating with the drug. It was only in vitro estimation, in vivo study is 
required to confirm high virulence. This finding seems to be in opposition to the theory of 
trade-offs, but consistent with a number of studies showing that that increased virulence and 
the antibiotic resistance often arise almost simultaneously, for instance [71]. However, the 
genetic mechanisms connecting virulence and antibiotic resistance are still unclear and a 
subject for extensive research in this field. 
 In this study, we obtained the bacterial strain resistant to transferrin. Despite the fact 
that this strain was able to tolerate 1000 µg/mL for 15 days, this ability was lost after 8 hours 
of culturing without transferrin. Thus, we concluded that the resistance to transferrin is non-
heritable. 
 Finally, we established the subtherapeutic dose of ciprofloxacin for future in vivo 
experiments to confirm transferrin efficacy in combination with antibiotics. 
 Together with the data from [20] our findings confirmed that the induction of iron 
starvation in bacteria results in the reduced rate of resistance to antibacterial agents, such as 
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ciprofloxacin and meropenem.  Moreover, transferrin prevents the emergence of virulence. 
Thus, transferrin can be considered as a good adjunct to traditional antimicrobial therapy and 
further characterization is recommended. This novel therapeutic strategy will be able to 
optimize current treatment for life-threatening Gram-negative infections and improve the 
clinical outcomes. If it is confirmed in vivo that transferrin improves the rate of killing and 
reduces the emergence of antibacterial resistance to widely-used antibiotics, the therapy 
would be rapidly clinically translated 
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Supplementary Materials 
S1. Protocol of resazurin-based time-kill assay 
Materials 
Department: Spellberg Lab, Institute for Genetic Medicine, Keck School of 
Medicine at USC
Procedure name: Resazurin-based time-kill assay for Acinetobacter baumannii
Author: Ksenia Ershova
Date of preparation: April, 7th, 2016
Version No: 1.0
Name Amount for 1 strain, 21 
groups, and 7 time 
points
Description
RPMI 1640 200 mL S te r i l e . T h e r mo F i s h e r 
Scientific, Cat# 11875085
Tryptic Soy Broth (TSB) 10 mL Sterile
Mueller Hinton II broth (MH2) 10 mL Sterile
PBS 100 mL Sterile
Tryptic Soy Agar (TSA) 150 mL Sterile
90 mm Polystyrene Round Petri dishes 9 Sterile
1.5 mL centrifuge tubes 10 Sterile
10 mL centrifuge tubes 1 Sterile
50 mL centrifuge tubes 2 Sterile
96-well U-bottom shape plate 1 Sterile
Shaker 1
Incubator 1
Centrifuge 1 Should fit all types of used 
tubes
Spectrophotometer 1 FLUOstar Omega plate reader 
(BMG LABTECH GmbH, 
Germany)
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Detailed description of procedures 
At all steps that indicate mixing should be vortexed thoroughly. 
Day 1 
1. Set up the overnight culture of the bacterial strain in 10 mL of Tryptic Soy Broth (TSB) in 
50 mL centrifuge tubes. Incubate for 8 hours at 37°C/200 rpm.  
Day 2 
1. Take 100 µL of overnight culture and add to 10 mL of Mueller Hinton II broth. Incubate 
for 2-3 hours at 37°C/200 rpm. Exact time of incubation depends on the strain and should 
be enough to reach log-phase of bacterial growth. 
2. Wash the culture 2x with PBS and resuspend in 10 mL of RPMI. Use centrifuge settings: 
speed = 3000 rcf, temperature = 20°C, time of spinning = 10 min. 
3. Measure OD600. Adjust it to 0.5 if needed using RPMI. 
4. Dilute 50 µL bacteria into 10 mL RPMI to make a working concentration of 106 CFUs/
mL.  
5. Plate bacteria to confirm initial CFU count: 
5.1.  Dilute bacterial culture in 100 times: take 10 µL of culture, add 990 µL PBS. 
5.2.  Dilute bacterial culture in 10 times: take 100 µL of culture, add 900 µL PBS. 
5.3.  Plate 100 µL of culture to the labeled Petri dish containing 10 mL of dried TSA in 3 
technical replicates. Dilution factor = 4 (to calculate CFU in 1 mL, number of 
colonies should be multiplied by 104).  
5.4.  Incubate plates for 24 hours at 37°C. 
6. Prepare a working concentrations of antibiotics in RPMI at 4x the desired experimental 
concentration.  
7. Set up the time-kill experiment in the 96-well U-bottom shape plate in the total volume 
220 µL: 
7.1.  Design an appropriate plate layout. Do not use edge wells. 
7.2.  Fill edge wells with 200 µL of PBS. 
7.3.  Add 100 µL of culture from step 4 into the wells according to plate layout. 
7.4.  Add 50 µL of the one antibiotic from step 6 into appropriate wells. 
Supplementary Materials P55
7.5.  Add 50 µL of the other antibiotic from step 6 or 50 µL RPMI into wells with only 
one antibiotic. 
7.6.  Add 20 µL of 0.1% aqueous resazurin solution to each well. 
7.7.  Incubate plate at 37°C/24 hrs. 
8. Set up the standard curve assay in the 96-well U-bottom shape plate in the total volume 
220 µL: 
8.1.  Fill edge wells with 200 µL of PBS. 
8.2.  Add 100 µL of RPMI to the each well from B to G at column 2. 
8.3.  Add 100 µL of culture from step 4 to the same wells. 
8.4.  Make serial 2-fold dilutions up to column 10. 
8.5.  Add put 200 µL of RPMI to column 12 (negative control). 
8.6.  Add 20 µL of 0.1% aqueous resazurin solution to each well. 
8.7.  Incubate at 37°C/24 hours. 
Day 3 
1. After 24 hours of incubation measure fluorescence by spectrophotometer (excitation 544 
nm, emission 590 nm, adjust gain for spectrofhotometer) for both 96-well plates. Define 
this time point as 0 hours. 
2. Measure fluorescence using the same settings at 1h, 2h, 4h, 6h, and 8h time points in the 
experimental plate. 
3. Count the number of colonies on the confirmation plates. 
4. Transform the results using appropriate dilution factor. Save the final results as a number 
of CFUs/mL. 
Day 4  
1. Measure fluorescence using the same settings at 24 hours time points in the experimental 
plate. 
2. Perform a data analysis, using R-scripts from here https://doi.org/10.5281/zenodo.572307 
and here  https://doi.org/10.5281/zenodo.572328. 
3. Plot median and interquartile range for each group at each time point.  
Reference documents 
1. Eliopoulos GM, Moellering RC, and Pillai SK. "Antimicrobial combinations." In Antibiotics in laboratory 
medicine, 365-424. Philadelphia, PA: Lippincott Williams and Wilkins, 2005. 
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2. Faria, Joana, Carolina B. Moraes, Rita Song, Bruno S. Pascoalino, Nakyung Lee, Jair L. Siqueira-Neto, Deu 
John M. Cruz, et al. 2014. “Drug Discovery for Human African Trypanosomiasis.” Journal of Biomolecular 
Screening 20 (1). SAGE Publications Inc STM: 70–81. doi:10.1177/1087057114556236. 
3. Zachari, Maria A., Panagiota S. Chondrou, Stamatia E. Pouliliou, Achilleas G. Mitrakas, Ioannis 
Abatzoglou, Christos E. Zois, and Michael I. Koukourakis. 2014. “Evaluation of the Alamarblue Assay for 
Adherent Cell Irradiation Experiments.” Dose-Response: A Publication of International Hormesis Society 
12 (2): 246–58. doi:10.2203/dose-response.13-024.Koukourakis. 
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S2. Protocol of CFU-based time-kill assay 
Materials 
Department: Spellberg Lab, Institute for Genetic Medicine, Keck School of 
Medicine at USC
Procedure name: Resazurine-based time-kill assay
Author: Ksenia Ershova
Date of preparation: April, 7th, 2016
Version No: 1.0
Name Amount for 1 strain, 7 
groups, and 5 time 
points
Description
RPMI 1640 200 mL S te r i l e . T h e r mo F i s h e r 
Scientific, Cat# 11875085
Tryptic Soy Broth (TSB) 10 mL Sterile
Mueller Hinton II broth (MH2) 10 mL Sterile
PBS 300 mL Sterile
Tryptic Soy Agar (TSA) 2300 mL Sterile
90 mm Polystyrene Round Petri dishes 210 Sterile
1.5 mL centrifuge tubes 300 Sterile
10 mL centrifuge tubes 8 Sterile
50 mL centrifuge tubes 2 Sterile
Shaker 1
Incubator 1
Centrifuge 1 Should fit all types of used 
tubes
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Detailed description of procedures 
At all steps of mixing prepared solution should be vortexed thoroughly. 
Day 1 
1. Set up the overnight culture of the bacterial strain in 10 mL of Tryptic Soy Broth (TSB) in 
50 mL centrifuge tubes. Incubate for 8 hours at 37°C/200 rpm.  
Day 2 
1. Take 100 µL of overnight culture and add to 10 mL of Mueller Hinton II broth. Incubate 
for 2-3 hours at 37°C/200 rpm. Exact time of incubation depends on the strain and should 
be enough to reach log-phase of bacterial growth. 
2. Wash the culture 2x with PBS and resuspended in 10 mL of RPMI. Use centrifuge 
settings: speed = 4300 rcf, temperature = 20°C, time of spinning = 10 min. 
3. Measure OD600. Adjust it to 0.5 if needed using RPMI. 
4. Dilute 50 µL bacteria into 10 mL RPMI to make a working concentration of 106 CFUs/
mL. 
5. Plate bacteria for confirm initial CFU count = 0 hours time point:  
5.1.  Dilute bacterial culture in 100 times: take 10 µL of culture, add 990 µL PBS. 
5.2.  Dilute bacterial culture in 10 times: take 100 µL of culture, add 900 µL PBS. 
5.3.  Plate 100 µL of culture to the labeled Petri dish containing 10 mL of dried TSA in 3 
technical replicates. Dilution factor = 4 (to calculate CFU in 1 mL, number of 
colonies should be multiplied by 104).  
5.4.  Incubate plates for 24 hours at 37°C. 
6. Prepare a working concentrations of antibiotics in RPMI at 4x the desired experimental 
concentration.   
7. Set up the time-kill experiment in 10 mL labeled tubes in the total volume 2 mL: 
7.1.  Add 1 mL of culture from step 4. 
7.2.  Add 0.5 mL of one antibiotic solution from step 6. 
7.3.  Add 0.5 mL of the other antibiotic solution from step 6 or 0.5 mL RPMI in groups 
with only one antibiotic 
7.4.  Incubate at 37°C 200 rpm for 1 hour. 
8. In 1 hour plate bacteria for CFU count at 1 hours time point: 
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8.1.  Take 10 µL aliquot from each experimental tube and add it to 990 mL of PBS = x100 
dilution 
8.2.  Plate 100 µL of culture from 8.1 to TSA plates. Plate 3 technical replicates. Dilution 
factor = 3 (to calculate CFU in 1 mL, number of colonies should be multiplied by 
103). 
8.3.  dilute bacterial culture in 10 times: take 100 µL of culture, add 900 µL PBS 
8.4.  plate 100 µL of culture to the labeled Petri dish containing 10 mL of dried TSA; 
repeat 3 times. Dilution factor = 4 (to calculate CFU in 1 mL, number of colonies 
should be multiplied by 104). 
8.5.  repeat the 10-fold dilutions if needed. Dilution factor will increase each time by 1. 
9. Plate 100 µL of bacterial culture in appropriate dilutions (e.g. 10-3 and 10-4) in triplicate at 
2 hours time point. 
2. Plate 100 µL of bacterial culture in appropriate dilutions (e.g. 10-4 and 10-5) in triplicate at 
6 hours time point. 
Day 3 
1. Plate 100 µL of bacterial culture in appropriate dilutions (e.g. 10-4 and 10-5) in triplicate at 
24 hours time point. 
2. Count the number of colonies on the plates from 0, 1, 2 and 6 hours time points. For each 
group, pick one dilution that contains between 50 and 500 colonies. 
3. Transform the results using appropriate dilution factor. Save the final results as a number 
of CFUs/mL. 
Day 4  
1. Count the number of colonies on the plates from 24 hours time point. Pick one dilution 
that contains between 50 and 500 colonies. 
2. Transform the results using appropriate dilution factor. Save the final results as a number 
of CFUs/mL. 
3. Perform data analysis. Plot median and interquartile range for each group at each time 
point.  
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S3. Resazurin-based time-kill assay results. Drug-susceptible strains 
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S4. Resazurin-based time-kill assay results. Drug-resistant strains 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S5. Standard curves for all strains in resazurin-based time-kill assay 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S6. Results of 24-hours mutants selection experiment 
Table S6.1. Selection for mutants resistant to ciprofloxacin and meropenem after 24 hours of those antibiotics 
exposure (in subinhibitory concentrations = 1/3 MIC) alone or in combination with 750 µL/mL of transferrin. K. 
pneumonia KP-nPDR#3.
Non-selective TSA Ciprofloxacin (16 µg/mL) selective TSA
Meropenem (16 µg/mL) 
selective TSA
group
sourc
e of 
data
colonie
s per 
plate
CFUs per 
1 mL of 
culture
colonie
s per 
plate
CFUs 
per 1 
mL of 
culture
Resistant 
colonies 
per 108 
CFUs
colonie
s per 
plate
CFUs 
per 1 mL 
of 
culture
Resistant 
colonies 
per 108 
CFUs
No drug
Exp#
3
793 7,93E+10 124 1240
1,416
22 220 0,251
958 9,58E+10 n/a n/a
Exp#
4
1081 1,081E+11 154 1540
1,419
0 0 0,000
1090 1,09E+11 n/a n/a
Exp#
5
1005 1,005E+11 116 1160
1,243
42 420 0,450
862 8,62E+10 n/a n/a
Transfe
rrin 750 
µg/mL
Exp#
3
619 6,19E+10 44 440
0,559
4 40 0,051
954 9,54E+10 n/a n/a
Exp#
4
940 9,4E+10 128 1280
1,329
0 0 0,000
986 9,86E+10 n/a n/a
Exp#
5
1045 1,045E+11 0 0
0,000
3 30 0,030
967 9,67E+10 n/a n/a
1/3 
MIC 
Ciprofl
oxacin
Exp#
3
813 8,13E+10 196 1960
1,692
n/a
1049 1,049E+11 119 1190 n/a
Exp#
4
986 9,86E+10 168 1680
1,949
n/a
856 8,56E+10 191 1910 n/a
Exp#
5
990 9,9E+10 186 1860
1,850
n/a
918 9,18E+10 167 1670 n/a
1/3 
MIC 
Ciprofl
oxacin 
+ 
transfer
rin 750 
µg/mL
Exp#
3
793 7,93E+10 68 680
0,853
n/a
825 8,25E+10 70 700 n/a
Exp#
4
1024 1,024E+11 65 650
0,607
n/a
1020 1,02E+11 59 590 n/a
Exp#
5
970 9,7E+10 0 0
0,000
n/a
918 9,18E+10 0 0 n/a
Exp#
3
995 9,95E+10 n/a 24 240
0,148
Supplementary Materials P65
1/3 
MIC 
Merope
nem
Exp#
3 1032 1,032E+11 n/a 6 60
0,148
Exp#
4
895 8,95E+10 n/a 58 580
0,347
1008 1,008E+11 n/a 8 80
Exp#
5
946 9,46E+10 n/a 96 960
0,926
1020 1,02E+11 n/a 86 860
1/3 
MIC 
Merope
nem + 
transfer
rin 750 
µg/mL
Exp#
3
995 9,95E+10 n/a 2 20
0,010
1032 1,032E+11 n/a 0 0
Exp#
4
895 8,95E+10 n/a 0 0
0,000
1008 1,008E+11 n/a 0 0
Exp#
5
946 9,46E+10 n/a 5 50
0,051
1020 1,02E+11 n/a 5 50
Table S6.2. Descriptive statistics of the experiment: “Selection for mutants resistant to ciprofloxacin and 
meropenem after 24 hours of the antibiotics exposure (in subinhibitory concentrations = 1/3 MIC) with or 
without 750 µL/mL of transferrin. K. pneumonia KP-nPDR#3.
Group # of 
replicates
median Q25 Q75 mean sd min max
Ciprofloxacin
no drug 3 1,142 1,330 1,418 1,359 0,101 1,243 1,419
transferrin 750 µg/mL 3 0,599 0,300 0,964 0,643 0,666 0,000 1,329
1/3 MIC ciprofloxacin 3 1,850 1,771 1,900 1,830 0,130 1,169 1,949
1/3 MIC ciprofloxacin 
+ transferrin 750 µg/
mL
3 0,607 0,304 0,730 0,487 0,439 0,000 0,853
Meropenem
no drug 3 0,251 0,126 0,351 0,234 0,226 0,000 0,450
transferrin 750 µg/mL 3 0,030 0,015 0,041 0,027 0,026 0,000 0,051
1/3 MIC Meropenem 3 0,347 0,248 0,637 0,474 0,404 0,148 0,926
1/3 MIC Meropenem 
+ transferrin 750 µg/
mL
3 0,010 0,005 0,031 0,020 0,027 0,000 0,051
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Table S6.3. Selection for mutants resistant to ciprofloxacin and meropenem after 24 hours of those antibiotics 
exposure (in subinhibitory concentrations = 1/3 MIC) alone or in combination with 750 µL/mL of transferrin. K. 
pneumonia KP-nPDR#4.
Non-selective TSA Ciprofloxacin (16 S/mL) selective TSA
Meropenem (16 S/mL) 
selective TSA
group
sourc
e of 
data
colonie
s per 
plate
CFUs per 
1 mL of 
culture
colonie
s per 
plate
CFUs 
per 1 mL 
of 
culture
Resistant 
colonies 
per 108 
CFUs
colonie
s per 
plate
CFUs 
per 1 mL 
of 
culture
Resistant 
colonies 
per 108 
CFUs
No 
drug
Exp#
2
98 9,8E+09 1 10
0,091
1 10 0,091
122 1,22E+10 n/a n/a
Exp#
3
919 9,19E+10 19 190
0,194
1 10 0,010
1038 1,038E+11 n/a n/a
Exp#
4
837 8,37E+10 4 40
0,047
0 0 0,000
859 8,59E+10 n/a n/a
Transfe
rrin 750 
S/mL
Exp#
3
974 9,74E+10 6 60
0,062
0 0 0,000
954 9,54E+10 n/a n/a
Exp#
4
1012 1,012E+11 3 30
0,032
0 0 0,000
876 8,76E+10 n/a n/a
1/3 
MIC 
Ciprofl
oxacin
Exp#
2
44 4,4E+09 1 10
0,610
n/a
38 3,8E+09 4 40 n/a
Exp#
3
902 9,02E+10 28 280
0,383
n/a
874 8,74E+10 40 400 n/a
Exp#
4
1150 1,15E+11 41 410
0,380
n/a
901 9,01E+10 37 370 n/a
1/3 
MIC 
Ciprofl
oxacin 
+ 
transfer
rin 750 
S/mL
Exp#
3
913 9,13E+10 1 10
0,022
n/a
917 9,17E+10 3 30 n/a
Exp#
4
1008 1,008E+11 1 10
0,010
n/a
956 9,56E+10 1 10 n/a
1/3 
MIC 
Merope
nem
Exp#
2
98 9,8E+09 n/a 1 10
0,153
98 9,8E+09 n/a 2 20
Exp#
3
710 7,1E+10 n/a 3 30
0,045
830 8,3E+10 n/a 4 40
Exp#
4
983 9,83E+10 n/a 8 80
0,062
948 9,48E+10 n/a 4 40
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1/3 
MIC 
Merope
nem + 
transfer
rin 750 
S/mL
Exp#
3
879 8,79E+10 n/a 0 0
0,000
778 7,78E+10 n/a 0 0
Exp#
4
1045 1,045E+11 n/a 3 30
0,015
981
9,81E+10
n/a 0
0
Table S6.4. Descriptive statistics of the experiment: “Selection for mutants resistant to ciprofloxacin and 
meropenem after 24 hours of the antibiotics exposure (in subinhibitory concentrations = 1/3 MIC) with or 
without 750 µL/mL of transferrin. K. pneumonia KP-nPDR#4
Group # of 
replicates
median Q25 Q75 mean sd min max
Ciprofloxacin
no drug 3 0,091 0,069 0,143 0,111 0,075 0,047 0,194
transferrin 750 S/mL 3 0,047 0,040 0,055 0,047 0,021 0,032 0,062
1/3 MIC ciprofloxacin 3 0,383 0,382 0,497 0,458 0,132 0,380 0,610
1/3 MIC ciprofloxacin 
+ transferrin 750 S/mL 3 0,016 0,013 0,019 0,016 0,008 0,010 0,022
Meropenem
no drug 3 0,010 0,005 0,051 0,034 0,050 0,000 0,091
transferrin 750 S/mL 3 0,000 0,000 0,000 0,000 0,000 0,000 0,000
1/3 MIC Meropenem 3 0,062 0,054 0,108 0,087 0,058 0,045 0,153
1/3 MIC Meropenem 
+ transferrin 750 S/mL 3 0,008 0,004 0,011 0,008 0,011 0,000 0,015
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S7. Protocol of 24 hours mutant selection 
Materials 
Department: Spellberg Lab, Institute for Genetic Medicine, Keck School of 
Medicine at USC
Procedure name: 24 hours mutant selection for Acinetobacter baumannii and K. 
pneumonia
Author: Ksenia Ershova
Date of preparation: April, 7th, 2016
Version No: 1.0
Name Amount for 1 strain, 6 
groups
Description
RPMI 1640 200 mL S te r i l e . T h e r mo F i s h e r 
Scientific, Cat# 11875085
Tryptic Soy Broth (TSB) 10 mL Sterile
Mueller Hinton II broth (MH2) 10 mL Sterile
PBS 300 mL Sterile
Tryptic Soy Agar (TSA) 1000 mL Sterile
Antibiotics & transferrin q.s. Sterile
90 mm Polystyrene Round Petri dishes 100 Sterile
1.5 mL centrifuge tubes 200 Sterile
10 mL centrifuge tubes 6 Sterile
50 mL centrifuge tubes 2 Sterile
Shaker 1
Incubator 1
Centrifuge 1 Should fit all types of used 
tubes
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Detailed description of procedures 
At all steps that indicate mixing should be vortexed thoroughly. 
Day 1 
1. Set up the overnight culture of the bacterial strain in 10 mL of Tryptic Soy Broth (TSB) in 
50 mL centrifuge tubes. Incubate for 8 hours at 37°C/200 rpm.  
Day 2 
1. Take 100 µL of overnight culture and add to 10 mL of Mueller Hinton II broth. Incubate 
for 2-3 hours at 37°C/200 rpm. Exact time of incubation depends on the strain and should 
be enough to reach log-phase of bacterial growth. 
2. Wash the culture 2x with PBS and resuspend in 10 mL of RPMI. Use centrifuge settings: 
speed = 3000 rcf, temperature = 20°C, time of spinning = 10 min. 
3. Measure OD600. Adjust it to 0.5 if needed using RPMI. 
4. Dilute bacteria with RPMI in 2 times to make a working concentration of 108 CFUs/mL.  
5. Plate bacteria for CFU count at initial culture:  
5.1.  Dilute bacterial culture in 100 times: take 10 µL of culture, add 990 µL PBS. 
5.2.  Dilute bacterial culture in 100 times: take 10 µL of culture, add 990 µL PBS. 
5.3.  Dilute bacterial culture in 10 times: take 100 µL of culture, add 900 µL PBS. 
5.4.  Plate 100 µL of culture on TSA plates in 3 technical replicates. Dilution factor = 6 
(to calculate CFU in 1 mL, number of colonies should be multiplied by 106).  
5.5.  Incubate plates for 24 hours at 37°C. 
6. Prepare a working concentrations of antibiotics and transferrin in RPMI at 4x the desired 
experimental concentration. 
7. Set up the the experiment in 10 mL labeled tubes in the total volume 2 mL: 
7.1.  Add 1 mL of culture from step 4. 
7.2.  Add 0.5 mL of one antibiotic solution from step 6. 
7.3.  Add 0.5 mL of transferrin solution from step 6 if needed or 0.5 mL RPMI in groups 
with only one drug. 
7.4.  Incubate plates for 24 hours at 37°C. 
Day 3 
1. Prepare TSA plates containing 16 µg/mL of antibiotic, dry it. 
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2. At the end of  24-hours incubation concentrate  the bacterial culture in each tube in 10 
times using centrifuge. 
3. Plate 100 µL of suspension on the selective plates corresponding to the group of 
treatment, plate in duplicates. 
4. Plate serial dilutions on the non-selective TSA for CFU count in suspension. 
5. Incubated plates at 37°C for 24 h 
Day 4  
1. Count the number of colonies on the plates. For non-selective plates pick one dilution that 
contains between 50 and 500 colonies. 
2. Transform the results using appropriate dilution factor. Save the final results as a number 
of CFUs per 1 mL. 
3. Calculate the proportion of resistant colonies by the number of CFUs in the culture 
4. Perform data analysis. Plot median and interquartile range for each group at each time 
point.  
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S8. The dynamics of antibiotics concentration in 20-days passage 
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S9. Macrophage Phagocytosis Assay 
Materials 
Department: Spellberg Lab, Institute for Genetic Medicine, Keck School of 
Medicine at USC
Procedure name: Macrophage phagocytosis assay 
Author: Ksenia Ershova
Date of preparation: April, 7th, 2016
Version No: 1.0
Name Amount for 1 bacterial 
strain, 6 groups
Description
Tryptic Soy Broth (TSB) 10 mL Sterile
Mueller Hinton II broth (MH2) 10 mL Sterile
Tryptic Soy Agar (TSA) 300 mL Sterile
Dulbecco’s modified Eagle medium
HBSS, sterile water 100 mL Sterile
Fetal bovine serum (heat-inactivated), 
complement-active CD-1 mouse serum, 
interferon-γ
q. s.
Hema 1-2 staining kit 30 Thermo Fisher Scientific, 
Cat#22-122911
MeOH 10
90 mm Polystyrene Round Petri dishes 100 Sterile
12-well plate 2 Sterile
1.5 mL centrifuge tubes 200 Sterile
10 mL centrifuge tubes 6 Sterile
50 mL centrifuge tubes 2 Sterile
Coverslips 12
Glass slides 6
Shaker 1
Incubator with high CO2 function 1
Centrifuge 1 Should fit all types of used 
tubes
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Detailed description of procedures 
At all steps that indicate mixing should be vortexed thoroughly. 
Day 1 
1.  Set up the overnight bacterial culture in 10 mL of Tryptic Soy Broth (TSB) in 50 mL 
centrifuge tubes. Incubate for 8 hours at 37°C/200 rpm. 
2. Set up stimulated RAW 264.7 murine macrophages in duplicate: 
2.1.  Set up 12-well plate with one circular glass coverslip in each well; add 1 mL 
Dulbecco’s modified Eagle medium with 10% fetal bovine serum (heat-inactivated) to 
each well. 
2.2.  Seed macrophages in the wells in final concentration 106 cells/well. 
2.3.  Add 1µL of murine Interferon-gamma (IFN-γ) for every 1 mL of cell culture. 
2.4.  Incubate overnight at 37°C with 5% CO2. 
Day 2 
1. Take 100 µL of overnight bacterial culture and add to 10 mL of Mueller Hinton II broth. 
Incubate for 2-3 hours at 37°C/200 r/min. Exact time of incubation depends on the strain 
and should be enough to reach log-phase of bacterial growth. 
2. Wash the culture 3 times with HBSS and resuspend in the same volume of HBSS. Use 
centrifuge settings: speed = 4300 rcf, temperature = 20°C, time of spinning = 10 min. 
3. Measure OD600. Adjust it to 0.5 if needed using HBSS. 
4. Plate bacteria for CFU count at initial culture:  
4.1.  Dilute bacterial culture in 200 times: take 5 µL of culture, add 995 µL PBS 
4.2.  Dilute bacterial culture in 100 times: take 10 µL of culture, add 990 µL PBS. 
4.3.  Dilute bacterial culture in 10 times: take 100 µL of culture, add 900 µL PBS. 
4.4.  Plate 50 µL of culture on TSA in 3 technical replicates. Dilution factor = 6 (to 
calculate CFU in 1 mL, number of colonies should be multiplied by 106).  
4.5.  Incubate plates for 24 hours at 37°C. 
Zeiss AxioImager light microscope with 
appropriate software
1
Name Amount for 1 bacterial 
strain, 6 groups
Description
Supplementary Materials P74
5. Take macrophages cell culture from incubator. Wash each well with 1 mL HBSS twice. 
6. Fill wells with 850µL of HBSS. 
7. Add 100µL of regular (non-heat-inactivated) or heat-inactivated CD-1 mouse serum. 
8. Add 50µL of bacterial culture with OD600 = 0.5 (2*108 CFUs/mL). 
9. Centrifuge plate at 300×g for 5min (9/9 acceleration & 1/9deceleration). 
10. Incubate plates at 37°C with 5% CO2 for 60 min. 
11. Stain Circular Glass Cover Slips: 
11.1. Remove media from wells and expel HBSS slowly, directly onto the coverslip. 
11.2. Aspirated HBSS in a circular motions around the well with a vacuum. 
11.3. Transfer coverslips into new 12-well plate. 
11.4. Repeat washing with HBSS twice. 
11.5. Add 1mL MeOH to each well, incubate ~1min, and then aspirate MeOH slowly. 
11.6. Add 1mL Hema-Stain I, incubate ~1min, and them aspirate Hema-Stain I. 
11.7. Add 1mL Hema-Stain II, incubate ~1min, and then aspirate Hema-Stain II. 
11.8. Wash each well with 1ml water 3 times. 
12. Label glass slides and transfer the coverslips turning them over. 
13. Dry slides overnight at room temperature. 
Day 3  
1. Perform the light microscopy at objective x1000. 
2. Take 5 images with at least 5 entire macrophages on the frame per slide. 
3. Count the number bacteria per macrophage for each image. 
4. Count the number of colonies on the confirmation plates. Transform the results using 
appropriate dilution factor. Save the final results as a number of CFUs/mL. 
1. Perform a data analysis. Plot median and interquartile range for each group. 
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S10. Patents related to the topic «the use of transferrin or lactoferrin in 
combination therapy to treat bacterial infections» 
Owners Patent Numbers Title Status
Pe
ndi
ng 
Ter
rito
rie
s
Gra
nte
d 
Terr
itor
ies
Prior
ity 
Date
Gran
ted 
Date
Expir
y 
Date
Total 
Cost 
[GBP]
Munchene
r App 
Kimme
EP110943A 
WO1983004370A 
DE3221881A 
EP96422A 
AU8316067A
Anti-parasitic esp. 
anti:malarial vaccine prodn. 
by growing parasite-infected 
erythrocytes in vino or in 
vitro in hypoferraemia 
conditions induced, e.g. by 
admin. of iron chelant
Rej
ecte
d
1982
-06-
09
1985
-06-0
5
0,0
CS8300921A Intravenous and intra-
peritoneal compsn. based on 
transferrin and 
immunoglobulin(s) IgG, IgA 
and IgM
Exp
ired
1983
-02-
10
1986
-08-1
4
1998
-02-1
0
CS8300975A Intravenous and intra-
peritoneal compsn. based on 
immunoglobulin IgG-7S and 
transferrin
Exp
ired
1983
-02-
14
1986
-08-1
4
1998
-02-1
4
National 
Research 
Developm
ent 
Corporatio
n
NO175735B 
NO8801288A 
AU8813543A 
DE3882781G 
CA1328071C 
DK173361B 
PT87065A 
GB2202851B 
US5587166A 
EP287206B1 
DK8801572A 
ZA8802076A
Proteinaceous material from 
Pasteurella grown with iron 
restriction useful in 
vaccination against 
Pasteurella infection esp. 
sheep and cattle
Exp
ired
1987
-03-
24
1990
-12-1
9
2008
-03-2
6
131143,6
EP401347B1 
WO1990006768A 
DE3842143C 
DE58909628G 
DE3844667C
Medical use of transferrin 
for endotoxin neutralisation
Exp
ired
1988
-12-
15
1990
-09-1
3
2000
-02-1
0
87233,2
Immuno 
Japan Inc | 
Chugai 
Pharmaceu
tical Co 
Ltd
EP431933B1 
CA2031746C 
DE69004941E 
US5198419A 
JP3181421A
Pharmaceutical compsns. 
contg. lactoferrin used to 
increase efficacy of beta-
lactam antibiotics in 
treatment of bacterial 
infection
Exp
ired
1989
-12-
08
1993
-03-3
0
2009
-12-0
8
99521,6
Baxter 
Internation
al Inc.
JP5070370A 
FI9201309A 
CA2063872C 
HU217071B 
AT402789B 
FI107779B1 
DE59207358G 
HU214059B 
AT9100651A 
EP506651B1
Drug contg. IgA, IgG and 
transferrin for treatment of 
microbial infection e.g. 
necrotising entero-colitis, 
inflammation and allergy
Exp
ired
1991
-03-
25
1996
-10-1
6
2005
-03-2
4
103836,3
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Immuno 
Japan Inc
DE69322896E 
EP559425B1 
US5576299A 
CA2090658A
Use of transferrin-lactoferrin 
family of proteins for 
potentiating host immune 
systems, partic. for treating 
or preventing opportunistic 
infections
Exp
ired
1992
-03-
02
1996
-11-1
9
2003
-01-1
5
15020,2
Morinaga 
Milk 
Industry 
Co. Ltd.
WO1993018061A
1 EP629213B1 
CA2102509C 
US5466669A 
AU667300B 
JP3188457B2 
AU9213609A 
JP7507763W 
NZ241911A
Immuno-stimulatory peptide 
derived from lactoferrin 
used for prevention and 
treatment of bacterial, fungal 
and viral infections
Exp
ired
1992
-03-
07
1995
-11-1
4
2012
-03-0
7
123846,4
Immuno 
Japan Inc
EP1013282A2 Use of transferrin or 
lactoferrin protein and 
bacteriostatic agent in foods 
or medicines to enhance 
phagocytic activity and host 
defense capacity for 
treatment of bacterial 
infections
Rej
ecte
d
1992
-04-
02
2005
-07-2
0
1334,6
Immuno 
Japan Inc
EP1013283A2 Composition for potentiating 
the immune system against 
opportunistic infections 
comprises a protein and a 
bacteriostatic agent
Rej
ecte
d
1992
-04-
02
2005
-07-2
0
1334,6
Immuno 
Japan Kk | 
Immuno 
Japan Inc
EP568200A2 
JP6145068A 
EP568200A3 
CA2093165A
Pharmaceutical and 
foodstuff compositions for 
immune system potentiation 
contain mammalian 
transferrin/lactoferrin 
protein and bacteriostatic 
agent useful for preventing 
infectious diseases caused 
by klebsiella pneumoniae
Rej
ecte
d
1992
-04-
02
2012
-04-0
2
6901,7
Immuno 
Japan Kk
JP5279266A Pharmaceutical compsn. for 
prevention and treatment of 
periodontal disease contains 
unmodified transferrin-
lactoferrin protein as active 
component
Rej
ecte
d
1992
-04-
02
2012
-04-0
2
5148,7
Microbo 
Srl | Pfizer 
Inc
JP8506098W 
AU690533B 
WO1994013318A
1 AU9458123A 
DE69324046E 
EP688226B1 
US5830489A 
IT1256702B 
FI9502949A
Synergistic transferrin 
protein compsn. for dental 
disorders is antibacterial, 
also prevents adhesion and 
invasion of bacteria, is made 
from natural sources and is 
non-toxic
Exp
ired
1992
-12-
17
1998
-11-0
3
2005
-12-1
5
73290,7
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Ichimaru 
Pharcos 
Inc
JP6279310A Antibacterial agent having 
strong antibacterial effect 
against normal skin 
pathogenic fungi without 
toxicity and stimulation 
compriss a hydrolyte of 
lactoferric acid with the 
iron=binding ability lost, 
that prevents pyodama by 
bacterial infection, tooth 
decay and peridontal disease
Rej
ecte
d
1993
-03-
31
2013
-03-3
1
5567,1
Morinaga 
Milk 
Industry 
Co. Ltd.
JP4059532B2 
JP8059500A
New peptide mixt. collected 
from lactoferrin 
hydrolysate(s) used for 
preventing opportunistic 
infection, infection with 
anaerobic bacteria and sepsis
Exp
ired
1994
-08-
15
2008
-03-1
2
2013
-12-2
8
12438,8
EP730868A1 
CA2169810A 
JP8217693A
Use of transferrin/lactoferrin 
type proteins to treat oral 
inflammation including 
aphthous stomatitis and 
gingivitis
Rej
ecte
d
1995
-02-
17
2015
-02-1
7
6404,0
Gambit Int 
Ltd
EP753309A2 
IT1278136B 
CA2180683A
Synergistic, broad-spectrum, 
non-toxic antiviral prepn. 
contg. transferrin and metal 
chelator, effective e.g. 
against herpes and 
rhinovirus infections of skin 
and mucosa
Rej
ecte
d
1995
-07-
12
2002
-01-0
2
15585,1
Microbo 
Srl
EP753308A2 
IT1278137B 
US5834424A 
CA2180689A
Treating or preventing Gram 
positive bacterial infections 
using lactoferrin to prevent 
invasion of host cells by 
bacteria, e.g. Streptococcus 
pyogenes or Staphylococcus 
aureus
Exp
ired
1995
-07-
12
1998
-11-1
0
2010
-12-2
8
23161,9
University 
Of 
California
US6054133A Novel composition for 
delivering antibiotics to 
intracellular pathogens, 
useful for treating or 
reducing mycobacterial 
infections, comprises 
antibiotic coupled to 
transferrin or low density 
lipoprotein
Gra
nted
US 1997
-07-
10
2000
-04-2
5
2017
-07-1
0
12076,3
Megmilk 
Snow 
Brand Co 
Ltd
JP11286452A 
JP4306828B2
Pathogenic bacteria and 
virus infection protection 
agent used along with food 
and beverage products 
consists of iron binding 
lactoferrin as active 
ingredient
Exp
ired
1998
-03-
31
2009
-08-0
5
2015
-05-1
5
10139,6
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Megmilk 
Snow 
Brand Co 
Ltd
JP11292788A 
JP4318765B2
Novel infection protection 
agent against Helicobacter 
pylori microbe for 
pharmaceutical and food 
products consists of iron 
bonding type lactoferrin 
active ingredient for 
opposing specific pylori 
microbe
Gra
nted
1998
-04-
01
2009
-08-2
6
2018
-04-0
1
10139,6
Lactoferri
n Products 
Inc
US20020054917A
1 CA2364984A1
Dietary supplement 
composition used for 
treating cancer, bacterial, 
fungal and viral infections 
and septicemia comprises 
beta glucan and lactoferrin
Inac
tive
US 1998
-08-
14
2018
-08-1
4
32040,6
Lytix 
Biopharma 
As
US20030148936A
1 US6890902B2 
WO2000012542A
2 
US20140037657A
1 
US20030022821A
1 AU9955268A 
CA2341037C 
US7439228B2 
EP1109827B1
Modified cytotoxic 
lactoferrin peptide useful for 
preparing pharmaceutical 
composition against 
bacterial infections and 
tumors and for inhibiting 
bacterial growth
Gra
nted
A
U
CA 
| 
DE 
| 
FR 
| 
GB 
| IT 
| 
US
1998
-08-
28
2005
-05-1
0
2018
-08-2
8
286420,5
Agennix 
Inc
MX251664B 
JP2002541066W 
CA2362153C 
CN1362969A 
WO2000049040A
3 
WO2000049040A
2 AU758150B 
EP1151009B1 
US20030105006A
1 
MX2001007956A
1 US6399570B1 
AU200028226A 
DE60036456E 
US7244706B2
Antimicrobial/endotoxin 
neutralizing polypeptide 
generated by proteolytic 
digestion of lactoferrin, 
useful for treatment of 
bacterial and fungal 
infections, and for 
preventing contamination of 
e.g. food products, living 
cells, and blood
Gra
nted
AU 
| 
DE 
| 
MX 
| 
US
1999
-02-
05
2002
-06-0
4
2019
-02-0
5
265785,5
Am 
Pharma 
Bv
AU200119015A 
US7060677B1 
AU776044B2 
DE60025026E 
EP1228097B1 
CA2388910C 
JP2003521483W 
WO2001034641A
2 
WO2001034641A
3
New polypeptides 
comprising the N-terminal 
region of human lactoferrin 
protein exhibit higher 
antimicrobial activity than 
the full length protein and 
are useful to treat bacterial 
infections
Gra
nted
AU 
| 
DE
1999
-11-1
1
2005
-12-2
1
2019
-11-1
1
182882,7
Glaxosmit
hkline Plc
AU200130758A 
US20030149256A
1 EP1244701A1 
US20020072596A
1 
WO2001046254A
1 
JP2003517847W
Isolated nucleic acid 
molecule encoding a human 
tranferrin protein is used in 
preventing, treating or 
ameliorating a medical 
condition
Inac
tive
A
U | 
JP | 
US
1999
-12-
23
2019
-12-2
3
101907,8
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Bovine 
Health 
Prod Inc
US20030095950A
1 US6660262B2
Broad-spectrum 
antimicrobial for treating 
bacterial, fungal and viral 
infections in animals e.g. 
cattle, comprises preset 
amount of trace mineral 
solution, Acidophilus, 
vitamin solution, cobalt 
amino acid chelates and kelp
Exp
ired
2001
-09-
28
2003
-12-0
9
2008
-01-2
9
22206,1
Pharmain 
Corp
US7790140B2 
CA2476589C 
US20100098636A
1 US7138105B2 
US8257682B2 
US20030224974A
1 
US20100069293A
1 
AU2003219922B
2 
JP2005524657W 
US20060239924A
1 
WO2003072143A
1 DE60335608E 
EP1478406B1
Biocompatible composition 
useful for the treatment of 
disease e.g. bacterial 
infection comprises a carrier 
with a metal binding 
domain, metal ion chelated 
to the metal binding domain 
of the carrier and an active 
agent
Gra
nted
AU 
| 
CA 
| 
CH 
| 
DE 
| 
FR 
| 
GB 
| IT 
| LI 
| 
US
2002
-02-
27
2006
-11-2
1
2022
-02-2
7
268797,0
Progine 
Farm Srl
WO2007065482A
1 
US20090156484A
1 CN101325965B 
US9050323B2 
EP1959988B1 
IT1367078B
Use of transferrin for 
preparing medicament for 
preventing or treating 
destructive inflammation 
affecting mucous 
membranes, optionally 
associated with states of 
hypoferremia, anemia, and/
or acute or chronic 
infections
Gra
nted
BE 
| 
CN 
| 
DE 
| ES 
| 
FR 
| 
GB 
| IT 
| 
US
2005
-12-
09
2012
-05-2
3
2025
-12-0
9
136303,5
Pharming 
Group Nv 
| 
Novathera 
Ltd
EP2054092A2 
US20100143490A
1 
WO2008023165A
2 
WO2008023165A
3
Composite material useful as 
pharmaceutical composition 
for preparation of 
medicament for treating 
wound, bacterial or viral 
infection comprises 
lactoferrin and bioactive 
glass
Inac
tive
US 2006
-08-
21
2026
-08-2
1
34119,1
Rq 
Bioscience 
Inc
EP2155251B1 
WO2009020481A
3 
WO2009020481A
2 
US20110038917A
1 CN101715349B
New inhalable, topical, or 
oral or buccal composition 
comprises at least two 
components, e.g. oligomeric 
proanthocyanidin, protease 
inhibitor, and lactoferrin, 
and a carrier, useful for 
treating gram negative 
bacterial infection and 
wound
Gra
nted
US CN 
| 
DE 
| 
FR 
| 
GB 
| PT
2007
-05-
08
2013
-09-2
5
2027
-05-0
8
92216,6
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Kedrion 
Spa
EP2162146B1 
IT1385511B 
WO2008142102A
2 
WO2008142102A
3
Use of apotransferrin for the 
preparation of 
pharmaceutical 
compositions useful for the 
treatment of bacterial 
infections as coadjuvants in 
antibiotic therapy
Gra
nted
DE 
| ES 
| 
FR 
| 
GB 
| IT
2007
-05-
21
2013
-12-1
8
2027
-05-2
1
73161,7
Los 
Angeles 
Biomedica
l Research 
Institute 
At Harbo
US20130310307A
1 
WO2013162742A
1
Killing infectious 
microorganism e.g. 
Staphylococcus and 
Aspergillus, or prophylactic 
treatment of individual to 
decrease likelihood of 
contracting microbial 
infection, or treating 
septicemia, involves 
administering transferrin
Pen
din
g
US 2012
-04-
26
2032
-04-2
6
21506,9
Case 
Western 
Reserve 
University
WO2014120774A
1 
US20150366948A
1
Treating fungal infection in 
e.g. human beings, involves 
topically administering 
amount of fungal iron 
acquisition inhibitor to 
human beings to treat fungal 
infection in human beings
Pen
din
g
US 2013
-01-
29
2033
-01-2
9
19529,5
Shenzhen 
Mckin Ind 
Co Ltd
CN104431286A Protein product used for 
boosting immunity, 
preventing bacterial and 
viral infection, and 
regulating iron balance in 
human body, comprises 
whey protein powder, 
lactoferrin, 
fructooligosaccharide, skim 
milk powder, and full cream 
milk powder
Pen
din
g
CN 2014
-11-0
3
2034
-11-0
3
12456,1
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